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ABSTRACT 
Head and neck squamous cell carcinoma (HNSCC) patients have a poor 
prognosis, with invasion, recurrence and metastasis as major causes of mortality. 
Currently, effective therapeutic options for advanced HNSCCs are still limited. The 
phosphatidylinositol 3-kinase (PI3K) pathway regulates a wide range of cellular 
processes crucial for tumorigenesis, and PIK3CA amplification and mutation are 
among the most common genetic alterations in HNSCC. Compared to the well-
documented roles of the PI3K pathway in cell growth and survival, its roles in tumor 
invasion, recurrence and metastasis have not been well delineated. 
Herein, I used a PIK3CA-genetically engineered mouse model (PIK3CA-
GEMM) in which PIK3CA is overexpressed in head and neck epithelium to mimic 
PIK3CA amplification in human HNSCC patients. I found that PIK3CA 
overexpression increased tumor invasiveness and metastasis by increasing de-
differentiation and epithelial-to-mesenchymal transition (EMT), and marked 
inflammation in tumor stroma. Molecular analysis suggested that progression of 
PIK3CA-driven HNSCC is facilitated by PDK1 and enhanced by TGF  signaling 
rather than by AKT.  Examination of HNSCC clinical samples revealed that both 
PIK3CA and PDK1 protein levels correlated with tumor progression, highlighting the 
iv 
 
significance of this pathway and providing a rationale for targeting PI3K/PDK1 and 
TGF  signaling in advanced HNSCC patients with PIK3CA amplification.  
EMT confers cancer stemness phenotype, and is believed to be involved in 
tumor recurrence and metastasis. Thus, I further explored the role of PIK3CA 
overexpression in regulating cancer stem cells (CSCs). I found that overexpression 
of PIK3CA enriches the CSC population. However, knocking down PIK3CA, or 
components in the PI3K pathway, paradoxically enhances CSC population. Protein 
array analysis revealed that CSC phenotype is associated with activation of multiple 
receptor tyrosine kinases pathways with Trk and Ephrin pathways the predominant. 
Pharmaceutical inhibitors targeting these pathways effectively eliminate CSCs both 
in vitro and in vivo. I also performed microarray analysis and identified histone 
deacetylase (HDAC) may contribute to EMT and CSC phenotypes in our models. In 
supporting this finding, I found that HDAC inhibitors effectively eliminate the CSC 
population in both murine and human HNSCC cells. Last, I did a microRNA array to 
identify potential candidates which may be essential for CSC maintenance. 
Preliminary studies showed that miR-18a-5p and miR-199a-5p may be involved in 
this process. In summary these data suggested that inhibitors targeting Trk, Ephs or 
HDAC pathways may be effective to treat recurrence and metastasis in HNSCC 
patients with PIK3CA amplification. 
The form and content of this abstract are approved. I recommend its 
publication. 
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Head and Neck Squamous Cell Carcinoma 
Head and neck cancers are composed mostly of head and neck squamous 
cell carcinoma (HNSCC) and salivary gland cancers. HNSCC refers to cancers 
derived from the squamous epithelium along the head and neck region, including 
nasal cavity, oral cavity and tongue, pharynx (nasal pharynx, oropharynx, 
hypopharynx) and larynx. Squamous epithelium is a layer of epithelial cells which 
can be organized either as a single layer in lung, or as a multiple layers (stratified) in 
head and neck region, skin, and cervix etc1,2. Cancers developed from these organs 
are referred to general as squamous cell carcinomas. HNSCC affects 650,000 
people and claims 350,000 lives annually3. Every year in the United States alone, 
there are 55,000 new cases of HNSCC and 15,000 deaths3. The 5-year survival rate 
for HNSCC is below 50% and has not been improved over the past several decades, 
which is largely due to locoregional invasion, recurrence and metastasis4. As 
invasion, recurrence and metastasis are the predominant causes of lethality in 
HNSCC patients, understanding the molecular mechanisms that regulate these 
processes is pivotal. A better therapeutic strategy that aims at controlling invasion, 
recurrence and metastasis is required to ultimately improve the poor prognosis of 
HNSCC patients. 
 




Etiological Factors for HNSCC  
HNSCC is a complex disease characterized by clinical and biological 
heterogeneity and is frequently caused by tobacco use, alcohol and human 
papilloma virus (HPV) infection5. In addition, there is a high incidence of HNSCC in 
Fanconi Anemia survivors at their early 20 to 30 years of age, suggests a genetic 
predisposition confers higher risk for developing HNSCC in this genetic 
disease6. Traditionally, HNSCC is often seen in male over 50 years old who have a 
heavy smoking and/or drinking history, and poor oral hygiene condition. Tobacco 
use is the single largest risk factor for HNSCC. Almost 85% of HNSCC is associated 
with tobacco use and the quantity of tobacco use directly links to the poor 
prognosis7,8.  Alcohol consumption is another major risk factor for HNSCC. Recently 
study also showed multiplicative joint effect between tobacco use and alcohol 
consumption on HNSCC risk9. 
HNSCC due to HPV infection represents another subtype of HNSCC, and 
incidence of HPV-related HNSCC keep increasing every year. It currently occupies 
over 25% of whole HNSCC cases5,10,11. The increased incidence of HPV-related 
HNSCCs, especially oropharyngeal cancers, among younger patients is likely due to 
engagement in oral sex10,11. Fortunately, HPV-positive HNSCCs appear to respond 
more favorably to radiation therapy than HPV-negative ones12, and vaccination 
agginst HPV is proposed with the hope to reduce HPV-associated HNSCC10. 
  
Molecular Alterations in HNSCC  




HNSCC tumorigenesis are depicted in Figure 1.1. Based on HPV and chromosome 
status, HNSCCs is divided into HPV+ (~25%) and HPV-/chromosome instability 
(CIN)+ (~65%) and HPV-/CIN- subgroups (~10%)4.  Most of studies before 2011 
focused on HPV-/CIN- HNSCC patients. As shown in Figure 1.1, deregulations of 
cell cycle –related genes, such as p16, p53, RB, CDKs and cyclinD1 are the major 
players for early stage of HNSCC tumorigenesis. Among those, inactivation of p16 
(mutation, genetic lose, or methylation) and p53 mutations are the most frequent 
genetic alterations.  Dysregulation of transforming growth factor beta (TGF ) 
signaling, such as loss, or reduced expression of TGF  type II receptor, Smad4, or 
overexpression of TGF 1 ligand, contributes greatly to malignant transformation and 
tumor progression13,14. Overexpression of epidermal growth receptor (EGFR) has 
been suggested as an important molecular event in HNSCC tumorigenesis (Figure 
1.1). The prevalence of EGFR overexpression in HNSCC (present in 80-90% of 
samples) is significant15. However, gene amplification of EGFR is only present in 
10–30% of samples and the EGFR mutation occurs in 1-7% of the tumor cell 
population15. These findings suggest that other mechanisms may be involved in the 
overexpression of EGFR in HNSCC. Thus, further study of EGFR homeostasis in 
HNSCC is critical for development of effective therapeutics. 
Alterations of the PI3K/AKT/PTEN pathway has been shown to be altered in 
HNSCC progression as shown in Figure 1.1. This is further validated and highlighted 
after a few seminal publications by whole-exome sequencing on large cohorts of 
HNSCC clinical samples from multiple institutions16–20. Two major findings from 

















Figure 1.1. A summary of molecular alterations in HNSCC tumorigenesis. 
Major genes and pathways involved in HNSCCs are depicted. This figure has 




frequent molecular alterations in human HNSCC patients and 2) Identification of 
somatic mutations of Notch molecules. 
The molecular alterations in HPV positive HNSCC are distinct from HPV 
negative HNSCC cases. HPV-16 is implicated in the pathogenesis of a HNSCC 
subgroup and the HPV viral oncogenes E6 and E7 are frequently overexpressed in 
the oropharynx of these patients21,22. A previous study reported a significant 
association between oropharyngeal cancer and oral HPV-16 infection and 
demonstrated that HPV exposure increased the risk of developing oropharyngeal 
cancer, regardless of tobacco and alcohol use11. Inactivation of p53 and RB by HPV 
E6 and E7 antigens is a well-recognized molecular mechanism for HPV positive 
HNSCC tumorigenesis10,23,24. Besides, HPV-positive HNSCCs have unique gene-
expression profiles and minimal mutations, while HPV-negative HNSCCs are 
frequently riddled with molecular and cytogenetic changes described above. 
Recurrence and metastasis are two major reasons for cancer death in 
HNSCC patients. Recurrence is highly associated with stage of primary tumors. For 
advanced stage of HNSCC patients, recurrence rate is as high as 30% within two 
years4,5. Node metastasis is frequent in HNSCC patients and correlated with primary 
tumor size25. Distant metastasis of HNSCC occurs in about 20% of HNSCC patients, 
with lung metastasis the most common5,26. The metastatic progression of HNSCC 
tumor cells is a multistep process that involves intimate interactions between tumor 
cells and their surrounding microenvironment27. Potential metastasis-related proteins 
include factors involves in epithelial-to-mesenchymal transition (EMT), cancer stem 




cytokines are also involved in these processes. For example, TGF 31, vascular 
endothelial growth factor (VEGF)32, platelet-derived growth factor (PDGF)33, 
fibroblast growth factor (FGF)34, interleukin-85 etc. have been shown to play 
important roles in HNSCC progression. Currently, both preclinical and clinical 
studies are evaluating the efficacy of antiangiogenic compounds (with or without 
chemotherapy) for the treatment of HNSCC35. Hopefully, these studies will spur the 
development of novel antiangiogenic and anti-metastatic agents for the treatment of 
HNSCC. Drugs targeting EMT and CSCs are hypothetically effective in 
preventing/treating recurrence and metastasis in HNSCC patients, in which are the 
major components of my thesis.  
 
PI3K Signaling Pathway in HNSCC  
The phosphatidylinositol-3-kinase (PI3K) signaling pathway is a major 
signaling component downstream of receptor tyrosine kinases (RTKs), and regulates 
multiple cellular functions such as survival, growth, migration, and metabolism. The 
PI3K family is comprised of three subclasses of lipid kinases. Among the three 
classes of PI3Ks, class IA PI3K is heavily linked to human cancers and is often 
activated by RTK signaling and Ras36. Class IA PI3K, a heterodimer consisting of a 
p85 regulatory and p110 catalytic subunit, phosphorylates phosphatidylinositol-
4,5,bisphosphate [PI(4,5)P2] in the cell membrane and generates the second 
messenger phosphatidylinositol-3,4,5,trisphosphate [PI(3,4,5)P3].  Following RTK 
signaling, adaptor subunit p85 binds to either phosphotyrosine residues or adaptor 




cell membrane. The p110 subunit phosphorylates PI(4,5)P2 to generate PI(3,4,5)P3. 
Further downstream, PI(3,4,5)P3 interacts with 3-phosphoinositide-dependent 
protein kinase (PDK1) and protein kinase B (AKT) and binds them to the plasma 
membrane36. In the plasma membrane, rapamycin (mTOR) complex 2 (mTORC2) 
phosphorylates AKT at Ser473, while PDK1 phosphorylates AKT at Thr30837 (Figure 
1.2). Activated AKT directly regulates multiple downstream molecules, such as 
mTORC1 and p70-S6, to transduce the major downstream PI3K signal pathway38–40. 
However, it has been shown that, in certain contexts, PI3K signaling and AKT 
activation can be uncoupled41–44.  
PI3K pathway is commonly altered in many human malignancies, including 
HNSCC. Recent whole-exome sequencing analysis of human HNSCC samples 
identified numerous molecular alterations in the PI3K pathway, such as gain-of-
function mutations and amplifications in PIK3CA and loss of heterozygosity and 
inactivating mutations in PTEN16–20 etc, which I will describe in detail below. These 
results highlight the importance of this pathway in HNSCC tumorigenesis and 
provide strong rationale of targeting this pathway for HNSCC treatment45. 
 
PIK3CA  
PIKγCA, which encodes the PIγK catalytic subunit p110α, is one of the most 
altered oncogenes in human cancers. Mutation of PIK3CA presents in ~12% of total 
human cancer samples from the data of the Catalogue of Somatic Mutations in 
Cancer (COSMIC) Database (http://www.sanger.ac.uk/genetics/CGP/cosmic/). 











Figure 1.2. Schematic of PI3K/AKT/mTOR signaling. Following RTK signaling, 
adaptor subunit p85 binds to either phosphotyrosine residues or adaptor 
molecules, which recruits the catalytic subunit p110 to form the heterodimer. The 
p110 subunit phosphorylates PI(4,5)P2 to generate PI(3,4,5)P3. Further 
downstream, PI(3,4,5)P3 interacts with 3-phosphoinositide-dependent protein 
kinase (PDK1) and protein kinase B (AKT) and binds them to the plasma 
membrane. In the plasma membrane, rapamycin (mTOR) complex 2 (mTORC2) 
phosphorylates AKT at Ser473, while PDK1 phosphorylates Thr308. Activated 
AKT phosphorylates numerous downstream regulators with the mTOR complex 1 





patients16,17,46,47, amplification of PIK3CA is more common, reaching to 40% in 
HNSCC patients38,40,48. Interestingly, PIK3CA amplification is also more frequent in  
squamous cell carcinomas of lung and cervix, suggesting its unique pathological role 
in squamous cell carcinomas38,40,48. Clinical correlation studies showed that PIK3CA 
alterations are associated with cancer recurrence, metastasis and poor clinical 
outcomes in various human cancers49–51. In HNSCC, a few clinical studies also 
showed that alteration of PIK3CA were correlated with advanced stage52,53, vascular 
invasion54 and lymph node metastasis55. 
Functionally, although the activated forms of PIK3CA transforms cells in 
vitro36, their oncogenic role in vivo was only recently investigated. In vivo, deletion or 
inactivation of PIK3CA halts oncogenic transformation and is resistant to Ras-
oncogene-induced tumorigenesis36,56. Overexpression of PIK3CA results in 
hyperplasia in ovarian surface epithelium and predisposes mammary glands to 
neoplastic transformation57. Additionally, a knock-in PIK3CA H1047R mutant is 
sufficient for lung and breast cancer development58,59. However, in HNSCC, our 
recent report showed that PIK3CA overexpression alone is not able to initiate tumor 
formation, but greatly promotes tumor progression and metastasis14. 
 
PI3K Isoforms  
The PI3K isoforms is summarized in Table 1.1. Among these isoforms, 
PIK3R1, which encodes the regulatory subunit p85α of class IA PIγK is also 
frequently mutated in human cancers. Somatic mutations in PIK3R1 occur in 7% of 
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Class I PI3Ks use phosphatidylinositol-4,5-
bisphosphate (PtdIns(4,5)P2) as their substrate. 






Cβ , PIγK-Cβ  
Class II PI3Ks use PtdIns as a substrate. Under 
certain condition, they might also use PtdIns-4-
phosphate (PtdIns4P) as substrate. Unlike class I 




Vps15, Vps34 There is only one catalytic member vacuolar 
protein sorting 34. Vps34 uses PtdIns as a 











interaction but retain a stabilizing interaction between p85α and p110α, resulting in 
aberrant activation of PI3K signaling62. 
The p110 , p110  and p110δ isoforms are also oncogenic in experimental 
settings. However, human cancer samples barely contain genetic alterations in 
these isoforms61. In a PTEN-GEMM prostate cancer study, ablation of p110 , not 
p110α, slowed prostate tumorigenesis63. Although, when a constitutively activated 
form of the p110  isoform was overexpressed, it induced prostate intraepithelial 
neoplasia in mice64. Furthermore, a breast cancer ERBB2-GEMM study showed that 
a catalytically inactive p110  knock-in halted tumor development65. For HNSCC, no 
such studies have been reported.  
 
Key Components in PI3K Signaling: PTEN, AKT, mTOR and PDK1  
PTEN, the second most commonly mutated tumor suppressor in human 
cancers, acts as a negative regulator of PI3K signaling by dephosphorylating 
PI(3,4,5)P3  (Figure 1.2). Inactivation of PTEN results in activation of AKT and 
mTOR, which are oncogenic in human cancers66. Somatic mutations of PTEN are 
rare in HNSCC (roughly 3% of cases), but loss of PTEN expression is more common 
and occurs in 30% of the cases67. A report showed that loss of PTEN expression is 
associated with tumor prognosis67. However, the mechanisms underlying loss of 
PTEN expression are still unknown68–71. 
AKT, a serine/threonine kinase, is considered the central mediator of the 
canonical PI3K pathway72. In general, activation of PI3K molecules or inactivation of 




changes73. AKT activation may be an early event in human HNSCC 
tumorigenesis, as persistent AKT activation occurs as early as the pre-malignancy 
stage, which includes dysplasia and carcinoma in situ74–76. 
There are three isoforms of AKTs (AKT1, AKT2 and AKT3) and all three 
isoforms are altered, although infrequent,  in multiple human cancers73,77. The most 
common mutation of AKT is an E17K missense mutation.78,79. However, there are no 
reports of the AKT1 E17K mutation in HNSCC80, but the mutation was detected in 
human SCCs of lung81. The E17K mutations at AKT2 or AKT3 genes were found in 
endometrial carcinoma77 and E17K mutation at AKT3 was also found in 
melanoma82. Mutation of AKT isoforms are barely present in HNSCC. 
Overexpression of AKT isoforms, especially AKT2, occurs in multiple human 
cancers83. At the mRNA level, AKT2 overexpression occurs in breast and colon 
cancers and is associated with cancer migration, invasion and metastasis84,85. AKT1 
and AKT3 overexpression is only observed in human gastric cancer83 and 
melanoma86, respectively. In HNSCC, one study reported AKT2 overexpression in 
tumor samples, but not AKT1 or AKT387. 
mTOR is one of the most intriguing signaling mediators of the PI3K/AKT 
pathway. mTORC1 and mTORC2 are the two distinct mTOR complexes. mTORC2, 
which contains Rictor, SIN1 and mLST8/GbL, activates AKT by phosphorylating 
Ser473 of AKT37. mTORC1, which contains Raptor, PRAS40 and mLST8/GbL, is 
activated by AKT to control key eukaryotic translational regulators, including p70-S6 
kinase and 4E binding protein 1 (4E-BP1)37. Additionally, mTORC1 phosphorylates 




phosphorylation stabilizes Grb10, which inhibits the PI3K and ERK-MAPK 
pathways88. Activation of mTOR/p70-S6/4E-BP1 pathway occurs frequently in 
human HNSCC specimens and cell lines; additionally, rictor amplification has also 
been reported47,89. Given its important function in PI3K/AKT pathway, targeting 
mTOR, such with rapamycin, is a promising approach for cancer therapy90. For 
example, rapamycin has been reported to be effective in treatment of HNSCC both 
in vitro and in vivo39,89,91. 
PDK1 is another serine/threonine protein kinase that phosphorylates 
members of the AGC kinase superfamily, including AKT.  Interestingly, PDK1 has 
been shown to regulate cell migration but not proliferation in lymphocytes92, and to 
promote EMT in cardiac development93. Compared to PTEN, AKT and mTOR, PDK1 
is relatively less studied in human cancers. Overexpression of PDK1 has been 
reported in several human cancers67,94,95 and correlates with disease progression in 
patients with pancreatic cancer or melanoma67,96. Invasion and activation of matrix 
metalloproteinase occurs during PDK1 overexpression97, while downregulation of 
PDK1 has an inhibitory effect on human breast cancer cells98. Interestingly, PDK1 is 
required for Kras-driven pancreatic cancer in murine models but not for the Kras-
driven lung cancer, suggesting a context-specific role of PDK1 in human cancers95. 
 
Crosstalk between PI3K Signaling and TGFβ Signaling in HNSCC 
Transforming growth factor beta (TGF ) is a multifunctional cytokine that 
regulates cell proliferation, apoptosis, tissue remodeling, immune function and 




proteins (BMPs) and activins/inhibins are all members of the TGF  superfamily99. 
The two types of transmembrane serine/threonine kinase receptors for TGF  
signaling are TGF  receptor I (TGF RI ) and TGF  receptor II (TGF RII). Major 
regulators of TGF  signaling are Smad family members, including receptor-activated 
Smads (R-Smads, Smad2 and 3), inhibitory Smads (I-Smads, Smad6 and 7) and the 
common Smad (Smad4)101. Phosphorylation of TGF RI leads to phosphorylation of 
R-Smads. Phosphorylated R-Smads form a complex with Smad4 and regulate gene 
expression at Smad binding elements, with interactions between the Smad 
complexes and other transcription factors. Attenuation of TGF  signaling is 
accomplished by I-Smads which bind to TGF RI and recruit ubiquitin ligases to 
degrade TGF RI and R-Smads101. Cross talk between PIγK and TGF  signaling can 
occur at multiple levels102. For example, Ligand-bound TGF  receptors activate MAP 
kinases, PI3K/AKT and Rho GTPase. On the other hand, PI3K is able to mediate 
TGF  receptor initiated intracellular signaling103 and antagonize TGF -induced 
cytostasis in some situations102. 
TGF  signaling plays a dual role in human cancers with a potent tumor 
suppressor at the early stage, and tumor promoter at the late stage of human 
cancers. Epithelial cells with defective TGF  signaling are hyper-proliferative, 
resistant to apoptosis and have increased genomic stability31. Tumor epithelial cells 
often exhibit a compensatory increase in TGF 1 ligand production, which further 
promotes tumor progression by increasing inflammation, angiogenesis in tumor 





Our lab has shown that loss or reduced expression of Smad4 and TGF RII is  
common in human HNSCC, and Smad4 or TGF RII GEMM gave rise to metastatic 
HNSCC, highlights the importance of this pathway in HNSCC development and 
progression13,107,108.  Conversely, altered TGF  signaling in tumor epithelial cells 
elaborate TGF 1 ligand overexpression in human HNSCC104. The TGF /SMAD and 
PI3K/AKT pathways, interplay each other in human cancer development and 
progression. In the early stages of cancer, PI3K/AKT pathway activation antagonizes 
the effects of TGF -induced growth-inhibition or cell death101. However, tumor cells 
are often more aggressive due to crosstalk between the TGF- /SMAD and 
PI3K/AKT pathways at late stage100,101,104. Targeting either or both pathways has 
been proposed including our lab for treating HNSCCs14,109. 
            
Mouse Models for HNSCC  
In vivo modeling of HNSCC, which recapitulates both the gross pathological 
and molecular features of human HNSCC patients, provides an excellent platform to 
investigate molecular mechanisms and testing novel therapeutics for HNSCC. Here, 
I will detail three types of mouse models for HNSCC. 
  
Chemically Induced HNSCC Mouse Models  
This refers to induction of murine HNSCC by applying chemical carcinogens 
to immunocompetent mice. One example is the carcinogen 7,12-
dimethylbenz[a]anthracene (DMBA)-induced Syrian hamster cheek pouch model110. 




premalignant mucosal lesions and SCCs, which share genetic/epigenetic alterations 
with human HNSCCs. These changes include H-ras mutation and overexpression of 
TGF 1111. However, hamster pouch mucosa tumors do not resemble human 
HNSCC anatomically and histologically. 
Another chemically-induced HNSCC mouse model uses 4-nitroquinoline-1 
oxide (4NQO), a water-soluble quinolone derivative to induce mouse HNSCC. 
4NQO induces DNA adduct forming similar to human tobacco carcinogen, mimicking 
tobacco exposure in human HNSCC patients112–115. The advantages of the 
chemical-induced HNSCC mouse models are 1) recapitulating an environment risk 
factor for HNSCC; 2) recapitulating tumor heterogeneity. The disadvantages are 1) 
the molecular alterations are not clear and less defined; 2) the doses of carcinogen 
used for the model may not be physiologically relevant116. However, combining 
chemical exposure with other mouse models such as genetically engineered mouse 
model may be the best system to illustrate the interaction between environmental 
risk factors and genetic alterations in HNSCC development or progression.  For 
example, we have recently shown that overexpression of PIK3CA promotes HNSCC 
progression by PDK1 and enhanced TGF  signaling by using such combined 
strategy14. 
 
Xenograft Models for HNSCC 
This refers to transplanting human HNSCC tumors either cell lines or fresh 
tumor tissues in immune-compromised mice117. The advantages of this model are: 




grow faster and are good for a quick in vivo study and drug screening. The 
disadvantages are: 1) the model lacks an intact immune system which is a critical 
part for cancer study; 2) it is not a naturally occurred tumor, and the tumor is a 
transplant. 
 
Genetically Engineered Mouse Models (GEMMs)  
GEMMs refer to using genetic engineered techniques to either overexpress a 
specific gene (transgenic), or delete a certain gene (knockout) in the mouse 
genome118.  The advantages are: 1) ideal model for investigating causal role of 
specific molecular alterations identified in human cancer patients.  2) naturally 
occurred tumors mimicking each stage of human cancer development and 
progression. The disadvantages are: 1) it relatively lacks of tumor heterogeneity; 2) it 
is labor intensive and takes longer time. 
The earliest GEMM for HNSCC is to overexpress cyclin D1 transgene in oral-
esophageal epithelium by using an Epstein-Barr virus lytic promoter119. However, 
this model used a conventional transgenic technique, in which the transgene level 
cannot be controlled, and was over physiologically relevant level in human patients. 
Therefore, our lab developed inducible head-and-neck-specific mouse models for 
HNSCC.     
  
Inducible Head-and-neck-specific Transgenic Mouse Models  
Our model system utilized the progesterone receptor (PR) system to allow for 




expression levels117,120. This inducible transgenic system contains both a 
transactivator line and a target line. As shown in Figure 1.3, the transactivator 
contains the Gal4 DNA binding domain, a truncated progesterone receptor ligand 
binding domain (ΔPR) and the NF-κB p65 transactivation domain. Activation of the 
the transactivator only occurs when ΔPR is bound to PR antagonist, RU486. RU486 
activates the transactivator in a dose-dependent manner. To target transgene 
expression in the basal layer of the stratified epithelia, the Keratin 5 (K5) or K14 
promoter are used. The target line consists of engineered GAL4 binding sites 
upstream of a tata minimal promoter and the target gene. When the transactivator 
and target lines are crossed, it produces double transgenic mice containing both 
genetic components. Following application of RU486, the transactivator binds the 
GAL4 binding site upstream of the target gene and drives expression of the target 
gene121 (Figure 1.3). The spatio-temporal control, and the ability to adjust gene 
expression level make it an ideal model to study the in vivo role of overexpressed 
genes identified in human HNSCC patients  
 
Inducible Head-and-neck-specific Knockout Mouse Models  
As shown in Figure 1.3, this system is based on the modification of the 
Cre/LoxP system. The Cre enzyme is a DNA recombinase derived from the 
bacteriophage P1 and works by initiating DNA recombination at loxP sites. The Cre 
enzyme is fused with ΔPR, which allow it to be controlled by RU486. Gene deletion 
is accomplished by flanking the target gene with loxP sites and activating Cre 















Figure 1.3. Schematic of inducible transgenic/conditional knockout mouse 
models. (A.) Inducible transgenic mouse models consists of a transactivator line 
and a target line. In the transactivator line, the keratin 5 or 14 is used to restrict 
expression of the GLp65 fusion protein to the stratified epithelia. GLp65 consists 
of a GAL4 DNA binding domain, the NF-kappaB p65 transactivation domain, and 
a RU486-inducible truncated progesterone receptor ligand binding domain. The 
target line consists of the gene of interest under the control of minimal tata 
promoter and four GAL4 DNA binding sites. Crossing of these two lines 
generates inducible transgenic mouse model. RU486 can be topically applied to 
induce transgene expression. (B.) For the inducible conditional knockout mouse 
model, Cre enzyme is fused with ΔPR to allow it to be controlled by RU486. Gene 
deletion is accomplished with Cre/LoxP system by flanking the target gene with 
loxP sites and activating Cre enzyme by RU486 to initiate recombination and 




target gene. Cre/LoxP has also been used in combination with other inducible 
promoters, such as tetra-cyclin, or estrogen receptor systems117,120. In addition, 
introduction of a new mutant gene can also be accomplished using the Cre/LoxP 
system, so called knock-in system. To initiate expression of a mutant gene, a floxed 
STOP cassette is placed before or after the target gene, which interrupts gene 
transcription. Once the Cre-PR1 fusion protein is activated, the floxed stop cassette 
is removed and the mutant gene is expressed.  
By using these systems, our lab and others successfully generated inducible 
head-and-neck-specific TGF , PIKγCA and AKT transgenic mouse models, and 
inducible head-and-neck-specific TGF RII, Smad4, PTEN, Kras knockout mouse 
models13,14,107,108,122, which can be used to study molecular mechanism of TGF  and 
PI3K pathway in HNSCC, and to test novel therapeutics for HNSCC. 
  
EMT, Cancer Stem Cells and Anti-Cancer Stem Cell Therapy 
 
Epithelial- to-Mesenchymal Transition (EMT) in HNSCC  
Epithelial-to-mesenchymal transition (EMT) is a process by 
which epithelial cells lose their cell polarity and cell-cell adhesion, and gain migratory 
and invasive properties to become mesenchymal cells. During embryonic 
development and wound healing, EMT allows for morphological alteration of 
epithelial cells123. Epithelial morphological changes breakdown cell-to-cell and cell-
to-extracellular matrix connections, which allows cell migration during tissue 




and metastasis and is associated with cancer  progression124–128. EMT is a feature in 
a subset of tumors of human HNSCC patients. In HNSCC patients, enhanced tumor 
cell migration and higher risk of metastasis are associated with E-cadherin loss and 
gain of vimentin, a molecular feature of EMT,  and overexpressed EMT-related 
transcription factors129,130124,131. 
TGF 1 is a potent EMT inducer in multiple human cancers, including 
HNSCC132. In addition,  it has been reported that Bmi1 regulates EMT through 
activation of AKT, stabilization of Snail, and repression of E-Cadherin133 in HNSCC. 
HNSCC cells with strong HIF-1α expression are capable of regulating EMT-
associated gene expression134. Given the strong association between EMT and 
HNSCC progression, understanding EMT process in HNSCC tumorigenesis will 
generate novel therapies to combat HNSCC progression.  
 
Cancer Stem Cells in HNSCC  
Cancer stem cells (CSCs) refer to cancer cells that possess the pluripotent 
characteristics of normal stem cells. It is hypothesized that CSCs contribute to 
cancer progression by forming tumors and sustaining themselves with self-
renewal/repair mechanisms135. CSCs promote resistance to chemotherapy and 
radiotherapy, and contribute to recurrence and metastasis136,137. Altogether, these 
characteristics support a role for CSCs in tumor initiation, recurrence and 
metastasis. 
Surgery and chemo-radiation therapies are still the major standard treatments 




early stage, over 20% of patients will relapse and die138. Platinum-based therapy 
provides better control over local disease, but the incidence of recurrence and 
distant metastases is increasing and the mortality rate for HNSCC patients with 
distant metastases reaches to ~90%139,140. CSCs may contribute to therapeutic 
resistance, recurrence and the formation of distant metastases27,30. Therefore, we 
believe that CSCs must be eliminated in order to achieve a cure for HNSCC 
patients. Currently, the putative markers for identification and isolation/enrichment of 
CSCs in HNSCC include surface markers CD44141,142, CD166143, CD24144, Side 
population (SP)145,  and aldehyde dehydrogenase 1 (ALDH1)146. CSCs can also be 
enriched by sphere formation assay147.  Besides these methods, c-Met148, CD98149, 
CD271150, CD200151 and CD10152 are recently reported as alternative CSC markers 
for HNSCC, although there markers are still controversial142,144,153. 
 
EMT and Cancer Stem Cells  
Interestingly, EMT and generation of CSCs are intricately connected in 
human cancers. The first example was found in breast cancer cells, where 
generation of stem cell traits in conjunction with EMT induction have been observed 
in mammary epithelial cells and breast cancer cells154. Further research revealed 
that EMT induction promoted tumor cell invasion, metastasis, drug resistance and 
enriched CSC populations in other types of human cancers123,155,156. In HNSCC, 
CSC-like CD44+ population is capable of switching a proliferative, epithelial-like, 
non-CSC phenotype into a migratory, mesenchymal and CSC-like phenotype157, 




overexpression of S100A4 in HNSCC cells promoted an EMT phenotype, 
accompanying with enhanced stem cell-like properties; conversely, S100A4 
knockdown reversed EMT and reduced self-renewal and tumorigenic properties in 
vitro and in vivo158.   
  
Anti-Cancer Stem Cell Therapy  
Traditional therapies often fail to prevent and/or treat cancer recurrence and 
metastasis30. CSC theory, although controversial, is believed to contribute to cancer 
recurrence and metastasis159, providing a promising opportunity for curing cancers.  
In general, there are two approaches to eliminate CSCs: 1) Agents that show 
specific or preferential cytotoxicity to CSCs; 2) agents that restore mesenchymal-to- 
epithelial (MET) state. The first example is salinomycin, a potassium ionophore that 
selectively destroys CD44high/CD24low breast CSCs in vitro and inhibits 
tumorigenesis in vivo160,161. The second example is PKA activation drugs, which are 
able to reverse EMT, and reduce CSC ability162. Studies on CSCs have also 
identified several CSC-related signaling pathways, such as Hedgehog163, Notch164–
166 and Wnt/ -catenin167,168 pathways. Drugs designed to target these pathways are 
developing in the hope of using them as anti-CSC therapies in future. 
  
Epigenetics and Targeted Epigenetic Therapy in Cancer 
Epigenetics refers to modification of gene expression rather than alteration of 
the genetic code itself169. Two major epigenetic modifications are histone 




pathogenesis of cancer and represent a novel approach to cancer therapeutics170.  
Histone deacetylation executed by histone deacetylase (HDAC) is the most 
important process of histone modification.  Histone deacetylation regulates 
chromatin remodeling and controls transcription in both normal cells and cancer 
cells170,171. DNA methylation at the CpG-rich regions of promoter also controls 
transcription of the gene, and has been shown as one of the mechanisms of 
silencing tumor suppressor genes in human cancers169. Given the important roles of 
both epigenetic processes in human cancers, targeting either histone deacetylation 
using HDAC inhibitors, or DNA methylation using demethylating agent have been 
used clinically for treating certain human malignancies172. For example, HDAC 
inhibitors have been found to block cancer cell proliferation and differentiation173,174 
induce apoptosis, and inhibit angiogenesis in human cancers175. Demethylating 
agents work by covalently bonding with DNA methyltransferase and preventing DNA 
methylation. Previous research indicates that demethylating agents such as 5-
Azacytidine are capable of inhibiting DNA methylation and associated 
oncogenesis176,177. 
Epigenetic modification is also frequently linked to certain key characteristics 
of CSCs. For example, silencing tumor suppressors with DNA methylation fuels CSC 
and promote tumor initiation, while hypomethylation of self-renewal and 
differentiation-associated genes supports CSC proliferation and metastasis178. 
BMP2/4 promotes differentiation of both normal and cancerous stem cell 
populations. When BMP receptor 1B (BMPR1B) is silenced, BMP2/4 supports 






miRNA Dysregulation in HNSCC  
MicroRNAs (miRNAs) are a class of small non-coding RNAs, ranging from 
19-25 nucleotides in length. miRNAs serve as regulators of post-transcriptional 
modification through targeting mRNAs by binding mRNA to inhibit its translation or 
target for degradation. A single miRNA can target hundreds of mRNAs and regulate 
multiple cell signaling pathways180. Given the diverse roles of miRNA in cell 
signaling, it is not surprising that miRNA dysregulation is linked to oncogenesis. In 
addition, miRNAs represent a new class of molecule for developing targeted 
therapies in cancer treatment181. 
Dysregulation of miRNA expression has been linked to tumorigenesis and 
dysregulated miRNAs may function as either tumor suppressors or oncogenes 180–
182 (Figure 1.4). For example, miR-17-92 cluster promotes tumorigenesis by 
increasing proliferation of cancer cells and deletion of miR-17-92 cluster slows down 
Myc-induced oncogenesis183. miR-21 overexpression is observed in breast cancer 
and is associated with advanced stage, lymph node metastasis and poor 
prognosis184; knockdown of miR-21 in breast cancer cells inhibits proliferation, 
migration, invasion and in vivo tumor growth185. miR-200 family miRNAs function as 
tumor suppressors and loss of these miRNAs promotes EMT and metastasis186. 
Changes in miRNA expression also commonly occur in HNSCC. The Let-7 miRNA 
family is down regulated in HNSCC187–190. Let-7a, inhibits expression of genes linked 













Figure 1.4. MicroRNAs targeting multiple hallmarks of cancer. Dysregulated 
microRNAs may function as either tumor suppressors or oncogenes to mediate 
cancer progression. This figure has been adapted from Iorio M V. et al. (2012) 




Another miRNA, miR-130b, is frequently overexpressed in HNSCC189,191 and is 
associated with EMT192 and downregulating tumor suppressor genes193. 
Amplification of miRNA locus, including miR-106b, miR-93 and miR-25, also occurs 
in HNSCC and is related to cancer cell proliferation189. 
Large subsets of HNSCC cases are plagued by recurrence, metastasis and 
subsequent death, which are likely caused  by CSCs194. Further research identifying 
specific miRNAs involved in CSC maintenance will contribute to the development of 
miRNA-based anti-CSC therapies for HNSCC. 
 
Current Standard of Care for HNSCC  
Most HNSCC patients present with advanced, stage III or IV disease, which 
require a combination therapy (usually chemotherapy, radiation and surgery). Stage 
I or II disease requires less aggressive treatment and have a better prognosis than 
patients with late stage HNSCC. However, they are still at risk of recurrence or  
metastasis, which are the two major challenges for treating HNSCC patients5. 
Currently, radiation therapy remains the primary treatment for oropharyngeal 
cancer, advanced hypopharyngeal and laryngeal cancer, while chemotherapy is 
essential for treating locally advanced HNSCC195. Induction chemotherapy is often 
administered with or prior to radiotherapy195. The only targeted therapy agents that 
are approved to treat HNSCC patients by FDA are inhibitors that target EGFR. 
Despite the usage of the third generation of these inhibitors, the median overall 
survival for patients with  recurrent or metastatic tumors remains less than 1 year195. 




the safety and efficacy of new treatments for HNSCC. A multicenter, randomized 
phase 3 trial tested a combination of docetaxel, cisplatin, and fluorouracil as 
induction chemotherapy for HNSCC patients, but only achieved modest results196. 
Studies are also analyzing the efficacy of EGFR inhibitors, including cetuximab and 
other monoclonal antibodies, for HNSCC treatment, but observed resistance after 
treatment197,198. Another class of potential therapeutic agents to treat HNSCC is 
tyrosine kinase inhibitors, which are administered orally and include the heavily 
studied drugs gefitinib199 and erlotinib200. Unfortunately, both gefitinib and erlotinib 
are only modestly effective against HNSCCs and gefitinib doesn’t improve survival 
rates over those of methotrexate201. 
Given the lack of effective treatments for HNSCC by current standard of care 
and rising incidence of this disease, there is an urgent need for novel therapies.  
Most recently, a promising avenue to treat HNSCC is the use of immune checkpoint 
inhibitors to unleash or enhance anti-cancer immune response. Recent clinical trials 
of PD1 antibody for the first line treatment of HNSCC, especially for the recurrent or 
metastatic HNSCC achieved some promising results202. There is no doubt that novel 
and effective therapies are highly desired to combat this devastating disease, 
particularly for fighting with disease recurrence and metastasis.  
 
Summary  
Prognosis of HNSCC patients has not been significantly improved over past 
decades. Treatment plans remain surgery, chemo-radiation and limited options of 




Investigation of underlying molecular mechanism in HNSCC progression has a hope 
to develop novel and effective treatment plans to improve patients’ survival. Both 
PI3K and TGF  signaling pathways are highly associated with human cancers, 
including HNSCC. We believe that interplay of these two pathways is at least one of 
the driven forces to promote HNSCC progression.  EMT and CSC are implicated in 
cancer recurrence and metastasis, which are the major causes for cancer deaths. 
Understanding molecular mechanisms responsible for these two processes in the 
context of deregulating PIγK/TGF  signaling will generate candidates for 
development as novel therapies to prevent/treat recurrence and metastasis of HNSC 















MATERIALS AND METHODS 
 
Cell Culture  
Cells were cultured from either 4NQO-induced control tongue SCCs 
(CUCONs) or 4NQO-induced PIK3CA-GEMM tongue SCCs (CU110s). Tumor 
tissues were minced with blade, and digested in 0.35% collagenase (Gibco, 
Carlsbad, CA, USA) followed by two rounds of 1% trypsin digestion at 37°C. Single 
cells were obtained through a cell strainer (70 m nylon, BD Biosciences, Franklin 
lakes, NJ, USA), and plated at 1 × 105/ml in 10cm dishes. The authentication of the 
cultured cells was validated by the transgene-specific genotyping PCR. The CU110 
and CUCON cells were maintained in DMEM (Corning Cellgro) supplemented with 
10% FBS (Sigma-Aldrich), streptomycin (100 mg/mL), and penicillin (100 IU/mL) in a 
5% CO2 incubator (37°C). 
UMSCC cell lines were obtained from the University of Michigan and VU cell 
lines from Vrije University at Netherland under MTA agreements Human HNSCC cell 
lines UMSCCs 1, 2, 47, VU1131, VU1365, Fadu, LNM1, Tu, HN6, CAL27, M4C and 
M4E were obtained and cultured as recommended by protocols provided by 
University of Michigan, Vrije University, or  ATCC. Basically these cells were 
cultured in DMEM (Corning Cellgro) supplemented with 10% FBS (Sigma-Aldrich), 






Cell Proliferation, Migration and Invasion Assays  
For the cell proliferation assays, CU110 and CUCON cells were seeded in 12 
well plates as a density of 5 x 104 cells per well in triplicate. For CU110 cell 
transfected with lentivial vectors, cells were plated in 12-well plates as 2.5 x 104 cells 
per well in triplicate. Cells were then counted by Vi-CELL cell counter (Beckman 
Coulter, CA, USA) at different time points. Briefly, cells in each well of 24-well plate 
were harvested by treating with trypsin. 800µL of diluted cell suspension was used 
for the cell viability analysis by using Vi-CELL counter. We also used Cell Counting 
Kit-8 (Dojindo, Japan) to quantify cell proliferation and viability according to the 
manufacturer’s manual. Briefly, 6 x 103 cells were seeded into each well of 96-well 
plate. After different time points, 100µL of Cell Counting Kit-8 reagent was added to 
each well and incubate at 37°C for 1.5 hours. The plate was then read by p late 
reader (Biotek Synergy II) at 450nM. 
For the cell migration assay, cells were plated in 12-well plates and wound 
scratches were made using a 200µl pipette tip when cells reach confluence. Cells 
were washed with PBS, photographed and incubated in a complete growth media for 
48 hours. Cells were then photographed using Walter Camera Microscope (Walter 
Technology). The extent of wound closure was quantified by measuring the distance 
between two sides of the scratched lines before and after 48 hours migration using 
Photoshop (Adobe Technology). Migrated distance was presented as pixels and 
multiple measurements were performed.  
Cell invasion ability was determined using the QCM ECMatrix Cell Invasion 




serum free media to the upper insert and compete media containing 10% FBS was 
added to the lower chamber. After 48 hours, the invasive cells on the lower surface 
of the insert were stained according to the manufacturer’s manual. The invasive cells 
were then counted using a microscope at multiple view fields. 
  
Stable Knocking Down Using Lentivir al-based shRNAs  
The following lentiviral-based vectors containing short hairpin (sh)-RNAs were 
purchased from Sigma Aldrich (Table 2.1). shRNA lentiviral transduction particles 
sh-PIK3CA-2 (TL501641V) and its relevant control shRNA (TR30021V, shCntrl-2) 
were obtained from Origene Technologies. For lentiviral transfection, 2.2 x 
104 CU110 cells (or 3.5 x 104 cells for Fadu/UMSCC47) were plated in each well of 
6-well plate and virus-containing media with 8 mg/mL polybrene (Millipore) was 
added at the second day. 48 hours later, complete media with puromycin (10 mg/mL 
for CU110 cells and 2 mg/mL for Fadu/UMSCC47 cells) was added. Cells were 
cultured with puromycin for 1 week to eliminate non-transduced cells. Knockdown 
efficiency was determined by quantitative real-time PCR and Western blotting 
analysis. 
  
HNSCC Sphere Formation Assay  
Either murine or human HNSCC cells or cells pre-treated with inhibitors were 
suspended at density of 4.0 x 105 cells/mL in serum-free DMEM (Corning Cellgro) 
medium and seeded into 96-well ultra-low attachment plates (Corning Incorporated) 








                                 Table 2.1. List of sh-RNAs. 






































48 hours, spheres (≥ 1.5 microns) were counted as an HNSCC sphere forming unit 
by using a bright field microscope (Leica). The data was presented by the average of 
three independent experiments. Spheroids were cultured in the serum-free DMEM 
medium for 2-12 weeks before mRNA extraction, protein isolation, histology, or in 
vivo experiments. 
 
FACS Analysis  
All antibodies used for FACS analysis were purchased from eBioscience 
unless specified otherwise. In Brief, murine or human HNSCC cells or cells treated 
with inhibitors were harvested and washed twice in PBS buffer, and suspended in 
PBS with 1% serum as a density of 1.0 x 106 cells/100 µL. Cells were then stained 
with fluorochrome-conjugated monoclonal antibodies for mouse CD24 (17-0242-82), 
human CD24 (17-0247-42), mouse/human CD44 (48-0441-82), for 1 hour on ice. 
After washing twice with ice cold PBS, cells were re-suspended in 400µL ice cold 
PBS with 1% serum. Propidium iodide (Sigma-Aldrich) was added (1µg/mL) to 
exclude dead cells for the analysis. A minimum of 50,000 events were recorded for 
all samples. All FACS analyses were performed on a Gallios (Beckman Coulter, CA, 
USA) and the data were analyzed using Kaluza (Beckman Coulter, CA, USA). 
The assessment of ALDH1 activity was conducted by using ALDEFLUOR 
assay (StemCell Technologies, Durham, NC, USA). The procedure was followed by 
the manufacture’s manual. In brief, the single cell suspension was washed twice in 
PBS buffer and then suspended in ALDEFLUOR assay buffer as a density of 0.8 x 




suspension and then 500 µL was transferred to a tube containing 5μL of 1.5 mM 
DEAB, a specific ALDH inhibitor. Cells were incubated at 37°C for 45 minutes. After 
washing twice with ice cold PBS, cells were re-suspended in 400µL of ice cold 
ALDEFLUOR assay buffer. Propidium iodide (Sigma-Aldrich) was added (1µg/mL) to 
exclude dead cells for the analysis. A minimum of 50,000 events were recorded for 
all samples. All flow cytometric analyses were performed on a Gallios (Beckman 
Coulter, CA, USA) and the data were analyzed using Kaluza (Beckman Coulter, CA, 
USA). 
For the side population analysis, cells were suspended in the complete 
DMEM medium as 1.0 x 106 cells/mL. Hoechst 33342 (Sigma-Aldrich) was then 
added at a final concentration of 5 µg/mL for CU110 and CUCON cells and 
1.5µg/mL for Fadu and UMSCC47 cells and the samples were incubated for 90 
minutes at 37°C. After staining, cells were washed twice with ice cold PBS and re-
suspended in 400 µL of ice cold PBS with 1% serum for FACS analysis using MoFlo 
XDP70 analyzer (Beckman Coulter, CA, USA). Immediate before the analysis, 
propidium iodide (Sigma-Aldrich) was added (1µg/mL) to exclude the dead cells. For 
the control reactions, CU110 or CUCON cells were incubated with 1 µmol of 
verapamil (or 0.7 µmol for Fadu and UMSCC47) for 30 minutes at 37°C prior to the 
staining by Hoechst 33342. 
  
Quantitative Real-time PCR  
Total RNAs were extracted using RNeasy kits (Qiagen). cDNAs for differential 




transcription kit (Applied Biosystems) according to the manufacturer’s instruction. 
cDNAs for miRNA expression analysis were synthesized using qScript microRNA 
cDNA synthesis kit (Quanta). Quantitative RT-PCR reactions were carried out in 
triplicate using iTaq Universal SYBR Green Supermix (Bio-Rad) and were run on 
CFX Connect Real-Time PCR Detection System (Bio-Rad Laboratories, INC, 
Hercules, CA). Gene expression levels were normalized to GAPDH and quantified 
using comparative CT method. The primer sequences used for gene expression 
analysis are listed in the Table 2.2. For miRNA expression analysis, miRNA-specific 
primer paired with universal primer was used to amplify the signal using the SYBR 
green-based RT-PCR system. miRNA expression levels were normalized to U6 and 
quantified using comparative CT method. The miRNA specific primer sequences are 
listed in the Table 2.3. 
  
Protein Analysis 
Protein was extracted using the methods in our lab14. For western analysis, 
antibodies against p110α (4β49s), total AKT (9β7βs), AKT1 (β9γ8s), AKTβ (β964s), 
phospho-AKTSer-473 (3787s), e-cadherin (3195s), vimentin (5741s), SOX2 (3579s), 
PDK1 (3438), phospho-PDK1 (Ser-241) (3061), phospho-SMAD2 (Ser-465/467) 
(3101), phospho-SMAD3 (Ser-423/425) (9520) and GAPDH (5174s) were 
purchased from Cell Signaling. Antibodies against p85α (ab719β5) and ki67 
(ab16667) were obtained from Abcam. Antibody against CD44 (550536) was 
obtained from BD Biosciences Pharmingen. Antibody against mouse K1 was 




         Table 2.2. Sequence of primers used for qPCR analysis.  
Gene Forward / 
Reverse  
Sequence  
CDH-1 F 5'-CATGTTCACTGTCAATAGGG 
CDH-2 R 5'-GTGTATGTAGGGTAACTCTCTC 
CDH-2 F 5'-ACAATCAACAATGAGACTGG 
CDH-2 R 5'-CGTATACTGTTGCACTTTCTC 
CDH-11 F 5'-CACAACAGACATCAGGAAAC 
CDH-11 R 5'-CTGTAACTATTGGCTGGTTG 
Vimentin F 5'-GAACCTGAGAGAAACTAACC 
Vimentin R 5'-GATGCTGAGAAGTCTCATTG 
ZEB1 F 5'-ATATGAGCACACAGGTAAGAG 
ZEB1 R 5'-TTCATGTGTTGAGAGTAGGAG 
ZEB2 F 5'-CAAACAAGCCAATCCCAGGAG 
ZEB2 R 5'-TCCAGAGGGTTTGCAAGGCTA 
SNAI-1 F 5'-AGTTGACTACCGACCTTG 
SNAI-1 R 5'-AAGGTGAACTCCACACAC 
SNAI-2 F 5'-GACACATTAGAACTCACACTG 
SNAI-2 R 5'-GACATTCTGGAGAAGGTTTTG 
TWIST-1 F 5'-GAGACCTAGATGTCATTGTTTC 
TWIST-1 R 5'-GAATTTGGTCTCTGCTCTTC 
TWIST-2 F 5'-CGCATACTCCTGTTCTTTAC 
TWIST-2 R 5'-CTCTTTATTGTTCCTGGGTG 
ETS-1 F 5'-CGGATTACTTCATCAGCTAC 
ETS-1 R 5'-AGTCGTTCTCATACTTGAGG 
FOXC2 F 5'-ACCAGGCTATTTTGTTCTTG 
FOXC2 R 5'-ATTTTATCATGGTGACGTGG 
KLF4 F 5'-CCCTTCGGTCATCAGTGTTAG 
KLF4 R 5'-GGACCGCCTCTTGCTTAAT 
FN-1 F 5'-CCTATAGGATTGGAGACACG 
FN-1 R 5'-GTTGGTAAATAGCTGTTCGG 
BMI1 F 5'-TCAGCAACTTCATCTGGTTAG 
BMI1 R 5'-CTGGACGACAGTCACATGTAT 
SOX4 F 5'-CCTCGCTCTCCTCGTCCT 
SOX4 R 5'-TCGTCTTCGAACTCGTCGT 
EZH2 F 5'-GCCCACCTCGGAAATTTCCTG 
EZH2 R 5'-CAGAGCACCTGGGAGCTGCTG 
MK1 F 5'-ACGCAGAGAATGAGTTCGTGA 




         Table 2.2. continued. 
MK5 F 5'-ACCCTCAACAACAAGTTTGCC 
MK5 R 5'-TCTGCTTTATGGTCTTGGTGC 
MK8 F 5'-AGCTGAGGCTGAAACCATGTA 
MK8 R 5'-TCTGGCCTTTGAGGGCTTCAA 
MK13 F 5'-ATTCAGCAACCAGGTAGTAGG 
MK13 R 5'-TGGTCTGGAACCATTCCTCAG 
MK14 F 5'-CGATGACTTCCGGACCAAGTT 
MK14 R 5'-TGAGGCTCTCAATCTGCATCT 
MK15 F 5'-TCAATGTGGAAATGGACGCAG 
MK15 R 5'-TGTTAGACGCCACCTCCTTGT 
PIK3CA F 5'-TGCCTGTGGGATGTATCTGAA 
PIK3CA R 5'-TGCAAAGCATCCATGAAGTCT 
PIK3CB F 5'-GTCTTGGATCGACTGGCTAAA 
PIK3CB R 5'-ACAACCAGCTTTCCTCCATAA 
PIK3CD F 5'-ACGAAGTCCAGGAGCATTTC 
PIK3CD R 5'-CCAGGAGCACAGCAAATAGA 
PIK3CG F 5'-TCCATCCTGCTGGACAATTAC 
PIK3CG R 5'-CGAAGCTGATTGGGCATTTC 
PIK3R1 F 5'-CTTGGAGATGATCGACGTACAC 
PIK3R1 R 5'-GCTCTGTAGTTCTTGGGCTAAA 
PIK3R2 F 5'-AGGGAAGAGGTGAATGAGAGA 
PIK3R2 R 5'-CGTGTACTCTCCTTGGATCTTG 
PIK3R5 F 5'-CAGGACAGCTTTGACATCCTAC 
PIK3R5 R 5'-CTCCTCTTCCTCCTCTTCATCA 
PIK3R6 F 5'-GGCACTCAGCCCATCTATTT 
PIK3R6 R 5'-GGAGTCTTGGATCTTCACCTTC 
PI3KC2A F 5'-CTGGAAGTGACACAAGGAAGAA 
PI3KC2A R 5'-CATGGAGCCTGAGAAGATCATAA 
PIK3C3 F 5'-GCTCAGCAGACCTTTGTAGAT 
PIK3C3 R 5'-CAAGGCCTGAAGTCTCTCATT 
PIK3CA-2 F 5'-GTATCCCGAGAAGCAGGATTTAG 
PIK3CA-2 R 5'-CAGAGAGAGGATCTCGTGTAGAA 
PIK3R1-3 F 5'-CTGTAGCCAACAACGGTATGA 
PIK3R1-3 R 5'-CGTCTGCTGTATCTCGAAGTTT 
PIK3R2-1 F 5'-CTGGACAGCGAATCTCACTAC 
PIK3R2-1 R 5'-GCCAGCAGGAAGCTCTTAAT 
-catenin F AGCGCTGTGTCCTCAGGTTATCAA 




         Table 2.2. continued. 
N-cadherin F ACAATCAACAATGAGACTGG 
N-cadherin R CGTATACTGTTGCACTTTCTC 
FoxC2 F ACCAGGCTATTTTGTTCTTG 
FoxC2 R ATTTTATCATGGTGACGTGG 
CD44 F TCTGCCATCTAGCACTAAGAGC 
CD44 R GTCTGGGTATTGAAAGGTGTAGC 
CD166 F CTGTGGTGTGGATGAAGGATAA 
CD166 R CCTGAAGAGCAGTTTCACAGA 
CD133 F CTGCCCAAGCTGGAAGAATA 
CD133 R CAAACACACCACACAGCAAG 
CD24 F ACCCACGCAGATTTACTGCAA 
CD24 R CCCCTCTGGTGGTAGCGTTA 
EZH2 F TCAAAACCGCTTTCCTGG 
EZH2 R TGTCCCAATGGTCAGCA 
BMI1 F TGACGAATGCTGGAGAGCTGGAAA 
BMI1 R TGGAAATGTGAGGGAACTGTGGGT 
KLF4 F GCGTGAGGAACTCTCTCACATGAA 
KLF4 R AAAGTCTAGGTCCAGGAGGTCGTT 
Wnt5a F ACTGGCAGGACTTTCTCAAGGACA 
Wnt5a R GCCTATTTGCATCACCCTGCCAAA 
PDK1 F AGACCTTTGGGCCCTTGGATGTAT 
PDK1 R ACAGCCTAAACGCTTTGTGGCATC 
PTEN F AATTCCCAGTCAGAGGCGCTATGT 
PTEN R GATTGCAAGTTCCGCCACTGAACA 
p16 F ACATCGTGCGATATTTGCGTTCCG 
p16 R ACATCGTGCGATATTTGCGTTCCG 
EGFR F GAAGCCTATGTGATGGCTAGTG 
EGFR R AGGGCATGAGCTGTGTAATG 
STAT3 F TGCTGCAAATGGAACTGCTTCTGG 
STAT3 R AGGAATCGGCTATATTGCTGGT 
CYCLIND1 F TGCTGCAAATGGAACTGCTTCTGG 
CYCLIND1 R TACCATGGAGGGTGGGTTGGAAAT 
KRAS F GGAGGGCTTTCTTTGTGTATTTG 
KRAS R GGCACATCTTCAGAGTCCTTTA 
HRAS F CACAGCAGGTCAAGAAGAGTAT 
HRAS R CTCGAAGGACTTGGTGTTGT 
NRAS F GAAAGCAAGTGGTGATTGATGG 




         Table 2.2. continued. 
TNFα F TTGTCTACTCCCAGGTTCTCT 
TNFα R GAGGTTGACTTTCTCCTGGTATG 
NF-κB1 F GGATGACAGAGGCGTGTATTA 
NF-κB1 R CCTTCTCTCTGTCTGTGAGTT 
IL-1 F GGTGTGTGACGTTCCCATTA 
IL-1 R ATTGAGGTGGAGAGCTTTCAG 
IL-6 F GATAAGCTGGAGTCACAGAAGG 
IL-6 R TTGCCGAGTAGATCTCAAAGTG 
IL-6R F GCCACCGTTACCCTGATTT 
IL-6R R GTTTCCTGTGGTAGTCCATTCT 
CCL2 F AGTAGGCTGGAGAGCTACAA 
CCL2 R GTATGTCTGGACCCATTCCTTC 
CCL3 F CTTCTCTGTACCATGACACTCTG 
CCL3 R GTGGAATCTTCCGGCTGTAG 
CCL9 F CCCTCTCCTTCCTCATTCTTAC 
CCL9 R CAGACTGCTCTGGACTTCTT 
CCR7 F GGTGGCTCTCCTTGTCATTT 
CCR7 R AAGTTCCGCACATCCTTCTT 
CXCL1 F TTCACCTCAAGAACATCCAGAG 
CXCL1 R AAGCCTCGCGACCATTC 
CXCL2 F TCAAGAACATCCAGAGCTTGAG 
CXCL2 R CTTCAGGGTCAAGGCAAACT 
CXCL5 F AGAAGGAGGTCTGTCTGGAT 
CXCL5 R GTGCATTCCGCTTAGCTTTC 
CXCL12 F GATCCAAGAGTACCTGGAGAAAG 
CXCL12 R TTTCTCTTCTTCTGTCGCTTCT 
CXCR2 F TGGGAGAATTCAAGGTGGATAAG 
CXCR2 R GACAGCATCTGGCAGAATAGAG 
CXCR4 F GAAGTGGGTTCTGGAGACTATG 
CXCR4 R CGACTATGCCAGTCAAGAAGAT 
TGF 1 F TAAAGAGGTCACCCGCGTGCTAAT 
TGF 1 R ACTGCTTCCCGAATGTCTGACGTA 
TGF 2 F AGAGGGATCTTGGATGGAAATG 
TGF 2 R TGAGGACTTTGGTGTGTTGAG 
TGF 3 F CCACGAACCTAAGGGTTACTATG 
TGF 3 R CTGGGTTCAGGGTGTTGTATAG 
TGF RI F GGGCTTAGTGTTCTGGGAAA 




         Table 2.2. continued. 
TGF RII F ACAACATCAACCACAACACGGAGC 
TGF RII R CCGATGGATCAGAAGGTACAAG 
Smad2 F ATCACAGCTTGGATTTGCAGCCAG 
Smad2 R AGAGCAAGCCTAAGCAGAACCTCT 
Smad3 F AGCCATTCCATTCCCGAGAACACT 
Smad3 R TGGTTCATCTGGTGGTCACTGGTT 
Smad4 F ACTGCTCAGCCAGCTACTTACCAT 
Smad4 R GGCTGGAATGCAAGCTCATTGTGA 
 
 
          Table 2.3. Sequence of primers used for qPCR analysis for microRNA. 
microRNA Sequence 
146b-5p 5'- CCCTGAGAACTGAATTCCATAGGCT 
214-5p 5'- CCCTGCCTGTCTACACTTGCTGTGC 
378-3p 5'- CCCACTGGACTTGGAGTCAGAAGGC 
199b-5p 5'- CCCCCCAGTGTTTAGACTACCTGTTC 
23b-5p 5'- CCCGGGTTCCTGGCATGCTGATTT 
199a-3p 5'- CCCACAGTAGTCTGCACATTGGTT 
194-5p 5'- CCCTGTAACAGCAACTCCATGTGGA 
199a-5p 5'- CCCCCCAGTGTTCAGACTACCTGTTC 
18a-5p 5'- CCCTAAGGTGCATCTAGTGCAGATAG 
20a-5p 5'- CCCTAAAGTGCTTATAGTGCAGGTAG 
17-5p 5'- CCCCAAAGTGCTTAGAGTGCAGGTAG 
708-5p 5'- CCCAAGGAGCTTACAATCTAGCTGGG 
106a-5p 5'- CCCCAAAGTGCTAACAGTGCAGGTAG 
18b-5p 5'- CCCTAAGGTGCATCTAGTGCTGTTAG 
182-5p 5'-CCCTTTGGCAATGGTAGAACTCACACCG 
19a-3p 5'- CCCTGTGCAAATCTATGCAAAACTGA 










For the Western blot, equal amount of total protein (30–35 g) were loaded 
onto an SDS-PAGE gel. After transferring to PVDF membrane, the blot was 
incubated with antibodies. Blot images were captured by either a ChemiDoc MP 
system (Bio-Rad Laboratories Inc.) or X-ray film (Kodak). TGF 1 ELISA was 




For the immunofluorescence (IF) staining, cells grown on the Lab-Tek II 
chamber slide system (Thermo Fisher Scientific Inc.) or frozen tissue sections of 
spheres were fixed in ice cold acetone for 10 minutes at 4°C. Slides were wash ed in 
PBS and blocked with 5% goat serum for 1 hour at room temperature. , then 
incubated with primary antibodies for 30 minutes. After washing with PBS for 3 
times, slides were incubated with either Alexa 488–conjugated (green; Invitrogen) or 
Alexa 594–conjugated (red; Invitrogen) secondary antibodies for 1 hour. After a final 
wash with PBS, coverslips were mounted with EverBrite Mounting Medium with 
DAPI (Biotium Inc.) and examined using a confocal microscopy. Double IF staining 
was performed as previously described13. Incubation with primary antibodies was as 
follows: Keratin 1 (K1; Convance Princeton, NJ, USA, PRB-165 P), K8 (Fitzgerald, 
Acton, MA, USA, β0 R-CP004), E-cadherin (Cell Signaling, Danvers, MA, USA, 
#3195), Vimentin (BD Pharmingen, San Jose, CA, USA, RV202) and Smad3 
(Novus, Littleton, CO, USA, 378611). 




buffered formalin, embedded in paraffin and sectioned to 5-μm thickness. Sections  
were stained with hematoxylin and eosin and examined for the presence of 
hyperplasia, dysplasia, papillomas, carcinomas and metastases. Tumor pathology 
and metastasis were examined by at least two investigators and confirmed by the 
head and neck cancer pathologist. IHC was performed as described previously14. 
Incubation with primary antibodies was as followings: PDK1 (Abcam, Cambridge, 
MA, USA, ab52893), CD45 (eBioscience, San Diego, CA, USA, 14-0451), F4/80 
(Serotec, Raleigh, NC, USA, MCA497GA), Gr1 (BD Pharmingen, 550291), CD11b 
(BD Pharmingen, 550282), p110α (Cell Signaling, #4β49), Ki67 (Abcam, ab16667) 
and pAKTSer473 (Cell Signaling, #3787). Slides were examined with a Leica 
microscope, and images were taken using the Q Capture Pro software (Q imaging, 
Surrey, BC, USA).Quantitation of IHC staining of human p110α, pAKT and PDK1 
was performed by two independent investigators using methods described 
previously14.  
  
Receptor Tyrosine Kinase (RTK) Antibody Array  
The PathScan RTK Signaling Antibody Array Kit was purchased from Cell 
Signaling Technologies and the procedure was performed according to the 
instruction of the manufacturer. Briefly, protein lysates were prepared by using RTK 
Array Lysis Buffer; protein lysate were then quantified and diluted to the same 
concentration before loading to the array chamber.  Detection antibody cocktail was 
then added to the chamber and incubate overnight at 4°C. After overnight, cha mber 




Streptavidin solution. Chamber slide was documented by using BIO-RAD ChemiDoc 
XRD imaging system and dot density was quantified by using Photoshop (Adobe). 
  
Microarray (Gene or microRNA) Analysis  
Total RNAs (including microRNAs) were extracted using TRIzol (Invitrogen) 
and RNeasy kits (Qiagen). RNA (including microRNAs) quality was examined using 
an Agilent 2100 Bioanalyzer. Basically, 200ng total RNA was used to amplify and 
label for generating biotinylated cRNAs. cRNAs were hybridized onto Affymetrix 
GeneChip (Mouse Gene 2.0 Chip for genes or miRNA 4.0 GeneChip for microRNAs) 
at the Genomics and Microarray Core of University of Colorado Anschutz Medical 
Campus. Scanned microarray data was processed by using GenePattern (Broad 
Institute) and ExpressionFileCreator to generate raw signal values. Pre-processed 
data was analyzed by Affymetrix Transcriptome Analysis Console 3.0 to generate 
hierarchical clustering. Differential gene expression analysis was performed by using 
Affymetrix Transcriptome Analysis Console 3.0. Differentially expressed gene sets 
were filtered based on a fold change >2, and the defaulted false discovery rate. 
Functional clustering analysis was done using both Affymetrix Transcriptome 
Analysis Console 3.0 and NIH David. 
 
MicroRNA Transfection  
Transfections of microRNAs or relevant mimics and inhibitors were performed 
using DpharmFECT Transfection Reagents (GE Healthcare) according to the 




and inhibitors along with DpharmFECT Transfection Agent (2µL/mL of medium) was 
used for transfecting 5 x 104 CU110 cells in a well of 24-well plate. Transfected cells 
were cultured for 48 hours for further experiments. 
 
Inhibitor Treatment  
Information of all inhibitors used is listed in Table 2.4. All inhibitors were 
prepared in DMSO as 10 mM stock. The effect of the various treatments on cell 
viability was evaluated by using two different methods. First method is based on 
using the Vi-CELL cell counter (Beckman Coulter, CA, USA). Briefly, cells were 
plated in 24-well plates at a density of 9.4 x 104 cells per well in triplicate. Cells were 
then treated with either vehicle (DMSO) or inhibitors. After 48 hours, cells were 
trypsinized and cell viability was measured by Vi-Cell cell counter (Beckman Coulter, 
CA, USA). The percentage of viable cells was defined as the ratio of cell number in 
inhibitor-treated group to that of the DMSO-treated group. IC50s were calculated 
using GraphPad Prism software. We also used Cell Counting Kit-8 (Dojindo, Japan) 
to quantify the cell viability according to the instruction manual.  
  
Animal Studies  
 
Generation and Characterization of Inducible Head-and-neck-specific PIK3CA 
Genetically Engineered Mouse Model (GEMM)   
All animal experiments were performed in accordance with protocols 
















Inhibitor  Vendor  Cat. No.  Target/s 
PX866 LC laboratories P-7501 pan-PI3K 
gefitinib Selleck Chemicals S1025 EGFR 
imatinib Selleck Chemicals S2475 c-kit 
axitinib Selleck Chemicals S1005 VEGFR 
ponatinib Selleck Chemicals S1490 Multi-RTKs 
AZD4547 Selleck Chemicals S2801 FGFR 
BMS-777607 Selleck Chemicals S1561 Axl, Ron,Tyro3 
GNF-5837 Selleck Chemicals S7519 TrkA/B/C 
OSI906 Selleck Chemicals S1091 IGF-1R, InsR 
PD325901 Selleck Chemicals S1036 MEK 
Stattic Selleck Chemicals S7924 STAT3 
GSK2334470 Selleck Chemicals S7087 PDK1 
LY2157299 Selleck Chemicals S2230 T R1 
Paclitaxel Selleck Chemicals S1150 Microtubule  
Everolimus Selleck Chemicals S1120 mTOR 
LDN211904 Merck Millipore 428201 Ephrin receptors 
Apicidin Cayman Chemical 10575 HDAC 
SAHA Cayman Chemical 10009929 HDAC 
TSA Cayman Chemical 89730 HDAC 
VPA Cayman Chemical 13033 HDAC 




Colorado Anschutz Medical Campus (UCAMC) and the Oregon Health and Science 
University (OHSU). The plasmid containing full-length cDNA of PIK3CA (pcDNA3.1-
PIK3CA) was obtained from Addgene (Cambridge, MA, USA) under the material 
transfer agreement. The PIK3CA fragment was subcloned into the target vector 
(ptata.A) using the XhoI site (Figure 2.1A). A 3.5-kb HindIII/KpnI fragment including 
Gal4-binding sites, minimal tata promoter and the PIK3CA cDNA was microinjected 
into the pronucleus of single-cell embryo by the transgenic mouse core facility at 
OHSU. The embryos were implanted into pseudo-pregnant females and allowed to 
develop to term. PCR genotyping was performed at the 3 weeks of age using 
genomic DNA isolated from tail biopsies. Three lines (#5840, #5446, #5703) 
transmitted the transgene through their germline and was called tata.PIK3CA mouse 
line thereafter (Figure 2.1B). The transgene-specific primers covering hemagglutinin 
tag were designed, along the upstream sequence. The primers used to detect the 
ptata.PIKγCA transgene were: forward: 5′-TGAGCAAGAGGCTTTGGAGT-γ′ and 
reverse: 5′-TGCATTCTAGTTGTGGTTT-γ′. 
The target mouse line tata.PIK3CA was then bred to the transactivator mouse 
line - K5.GLp65, which was developed previously13. The resulting bigenic mouse line 
K5.GLp65/tata.PIK3CA is hereafter referred to as PIK3CA-GEMM. The PIK3CA-
GEMMs were selected by using genotyping primers specific for GLp65 (forward: 5′- 
TGTCAAGGTCTTCTCGAGGA-γ′; reverse: 5′-GGCCATACACTTGAGTGACA-γ′), 
and the same primers that were used for detection of the PIK3CA transgene. 
All mouse experiments were performed in a C57BL/6 background. Adult 








Figure 2.1. Creation and identification of the target mouse line tata.PIK3CA. 
(A.) Subcloning strategy to make the target vector ptata.PIK3CA. (B.) Genotyping 
PCR using transgene specific primers to identify candidate mouse lines 
tata.PIK3CA, in which the transgene is transmitted through the germline. The 




transgenic mice (around 1-month-old) were treated with RU486 for PIK3CA gene 
induction and with the rodent oral carcinogen, 4NQO (Sigma, St Louis, MO, USA). 
For the transgene induction, 100μl of RU486, dissolved in sesame oil (0.β μg/ml), 
was applied in the oral cavity of mouse to induce either acute or sustained PIK3CA 
transgene expression as described previously13. For the oral carcinogenesis 
experiment, 4NQO (Sigma) was prepared weekly in propylene glycol at a 
concentration of 5 mg/ml, and was placed into drinking water in a final concentration 
of 50 μg/ml. The water was changed once weekly, and was given to mice for 16 
weeks. The general health condition of mice was monitored twice weekly, and their 
body weight was measured once weekly. Mice were given softened food when there 
were signs of food-intake difficulty, or decreased body weight. At the end of animal 
experiment, mice were euthanized. Buccal mucosa, tongue, lymph node and lung 
tissues were harvested for histological analysis and immunostaining. 
 
In-vivo Tumorigenicity Study 
For in vivo tumorigenecity study of HNSCC spheres, mono-layer growing or 
sphere-growing CU110 cells were injected subcutaneously to the left and right flanks 
of C57BL/6 mice at 1 x 104 or 1 x 103 cells per injection. Tumor growth was 
monitored for 1 month. After 1 month, mice were euthanized and tumors were 
harvested for the subsequent volume measurement. Tumor volume was calculated 
by the formula: tumor volume ¼ (length width width)/2. For the tail vein injection 
experiment, 1x105 inhibitor-treated or DMSO-treated CU110 cells were intravenously 




euthanized and their lung tissues were collected for gross assessment and 
hematoxylin/eosin (H&E) staining. 
  
Human HNSCC Clinical Sample Study  
The clinical study protocol was approved by the Institutional Review Board-
approved of UCAMC and OHSU, and written informed consent was obtained from all 
participants before sample collection. HNSCC and case-matched adjacent tissue 
samples were surgically resected from consenting patients at the Department of 
Otolaryngology of UCAMC and OHSU. Tissues examined in this study include a 
total of 74 HNSCCs (26 SCCs of tongue, 19 SCCs of oral cavity, 3 SCCs of nasal 
pharynx, 7 SCCs of oropharynx, 7 SCCs of hypopharynx, 12 SCCs of larynx) and 
case-matched tissues adjacent to tumors, and 24 cases of lymph node metastases. 
A total of 12 normal oropharyngeal samples from sleep apnea patients were used as 
normal controls. 
  
Statistical Analysis  
Statistical calculations were performed using Prism 5 software (GraphPad 
Software Inc.). Data were presented as the mean ± SDs as indicated in the figure 
legends. The statistical significance of quantitative data was determined using two-
tailed Student t test and results were presented as p values (P < 0.05; P < 0.01; and 







OVEREXPRESSION OF PIK3CA IN MURINE HEAD AND NECK EPITHELIUM 
DRIVES TUMOR INVASION AND METASTASIS THROUGH PDK1 AND 
ENHACNED TGFβ SIGNALING 1 
 
Introduction 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common 
cancer worldwide, with 350,000 deaths every year203. There are 55,000 new cases 
and over 15,000 deaths from HNSCC annually in the United States204. The most 
common etiological factors for HNSCC are tobacco exposure, alcohol and human 
papilloma virus infection4. Although tremendous efforts have been made to improve 
the treatment for HNSCC patients, HNSCC remains a lethal disease, with 5-year 
survival rates below 50%, a number that has not significantly changed in several 
decades204. Locoregional invasion, recurrence and metastasis are largely 
responsible for the poor prognosis of HNSCC patients. However, the underlying 
molecular mechanisms for HNSCC progression are still poorly understood. 
The phosphatidylinositol 3-kinase (PI3K) signaling pathway is a key mediator 
of cell survival, growth and metabolism, and is commonly altered in many human 
malignancies, including HNSCC38,40,48. The PI3K family is comprised of three 
subclasses of lipid kinases. Class IA PI3K, composed of a heterodimer between 
______________ 
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Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis 
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p110 catalytic subunit and a p85 regulatory subunit, has been intensively studied 
and demonstrated to be commonly altered in human cancers38,40. PI3K 
phosphorylates phosphotidylinositol-4,5,bisphosphate to phosphotidylinositol-
3,4,5,trisphosphate, a reaction which is antagonized by the tumor-suppressor 
phosphatase and tensin homolog (PTEN). In turn, phosphotidylinositol-
3,4,5,trisphosphate binds a subset of pleckstrin homology domain-containing 
proteins, including AKT and 3-phosphoinositide-dependent protein kinase (PDK1). 
AKT is activated by phosphorylation on serine 473 by the mTORC2 complex, and on 
threonine 308 by PDK1. Activated AKT directly regulates multiple downstream 
molecules, such as mTORC1 and p70-S6, to transduce the major downstream PI3K 
signal pathway38,40. However, it has been shown that, in certain contexts, PI3K 
signaling and AKT activation can be uncoupled41,42,205. 
Recent exome sequencing in human HNSCC samples revealed that 
molecular alterations in the PI3K pathway are the most common genetic changes in 
HNSCC patients’ cells16,17,46. Among those changes, PIK3CA, the gene coding for 
the p110α catalytic subunit of PI3K, is most frequently altered through either gene 
amplification or gain-of-function mutations16,17,46. Over 40% of HNSCC cases 
exhibit PIK3CA amplification38,40,48, and ~10% harbor PIK3CA gain-of-function 
mutations16,17,46. Although several studies suggest PIK3CA alterations correlate with 
advanced HNSCC stage16,52,53, vascular invasion206 and lymph node metastasis55, 
there are no in vivo studies that have elucidated the mechanisms by 
which PIK3CA alterations lead to HNSCC development and progression. 




genetically engineered mouse model (GEMM), in which PIK3CA is overexpressed in  
head and neck epithelium. Our results showed that in this GEMM overexpression 
of PIK3CA alone resulted in head and neck epithelial hyperplasia but was not 
sufficient to initiate tumorigenesis. However, overexpression of PIK3CA significantly 
increased susceptibility to oral carcinogen-induced head and neck tumorigenesis. 
Strikingly, PIK3CA overexpression promoted HNSCC invasion and metastasis 
through epithelial-to-mesenchymal transition (EMT) and enrichment of putative head 
and neck cancer stem cells (CSCs). Further molecular studies showed that 
activation of PDK1 and enhanced transforming growth factor  (TGF ) signaling play 
an important part in HNSCC progression. Our findings highlight the key role of PDK1 
and TGF  signaling in HNSCC invasion and metastasis, and suggest that targeting 
PDK1 and TGF  signaling may be effective approaches to controlling HNSCC 




Overexpression of PIK3CA in Murine Head and Neck Epithelia Resulted in 
Increased Susceptibility to Head and Neck Carcinogenesis 
Although PIK3CA amplification/mutation has been described in human 
HNSCC, little is known about its in vivo role during head and neck tumorigenesis. To 
this end, we developed an inducible, head-and-neck-specific PIK3CA genetically 
engineered mouse model (PIK3CA-GEMM) using previously published methods13. 




target mouse line (tata.PIK3CA; Figure 3.1A). In the transactivator line, the keratin 5 
(K5) promoter is used to restrict expression of the GLp65 fusion protein to the basal 
layer of stratified epithelia (for example, buccal mucosa, tongue). GLp65 consists of 
a GAL4 DNA-binding domain, the NF-κB p65 transactivation domain and an RU486-
inducible truncated progesterone receptor ligand-binding domain (ΔPR-LBD). The 
K5.GLp65 mice were bred to the tata.PIK3CA mice to generate the bigenic 
K5.GLp65/tataPIK3CA (hereafter referred to as PIK3CA-GEMM). The monogenic 
K5.GLp65 and tata.PIK3CA mouse lines were used as experimental controls. 
Starting at 4 week of age, mice were orally treated with RU486 dissolved in sesame 
oil. As shown in Figure 3.1B, upon RU486 application, the expression level of 
PIK3CA mRNA increased about 8- to 10-fold in the buccal mucusa and tongue 
tissues from the PIK3CA-GEMM compared with those from the control mice or the 
PIK3CA-GEMM without RU486 application. Correspondingly, the protein level of 
p110α (encoded by the PIKγCA gene) was also increased in PIKγCA-GEMM head 
and neck tissues upon RU486 application (Figure 3.1C). 
After verifying induced expression of PIK3CA in the PIK3CA-GEMM head and 
neck epithelia following RU486 administration, we treated PIK3CA-GEMMs with oral 
RU486 (β0 μg/mouse) twice weekly. Epithelial hyperplasia and carcinoma in situ with 
increased cell proliferation were observed in both buccal mucosa and tongue tissue 
as early as 6 months after initiation of treatment (Figure 3.1D). However, these 
premalignant lesions failed to progress into squamous cell carcinomas (SCCs), 





One of the major etiological factors of human HNSCC development is 
tobacco exposure4. To mimic this human situation and investigate the interaction 
between environmental factors and genetic susceptibility, we applied the 4-
nitroquinoline 1 oxide (4NQO)-induced HNSCC carcinogenesis protocol to the 
PIK3CA-GEMM. 4NQO is a DNA adduct-forming agent widely used as a tobacco 
surrogate to induce HNSCC in mouse models207. As shown in Figure 3.2A, PIK3CA-
GEMM and control mice were treated with RU486 applied orally twice weekly and 
with 4NQO added to drinking water (50 μg/ml) starting when the mice were 1-month 
old. Mice were exposed to 4NQO for 16 weeks, and received RU486 through the 
end of the 12-month experiment. PIK3CA overexpression significantly enhanced 
susceptibility to 4NQO-induced head and neck carcinogenesis (Figure 3.2B). By 5 to 
6 months of age, 39% of PIK3CA-GEMMs developed HNSCC, compared with only 
8% of control mice (P<0.01). By 10–12 months, all 4NQO-treated control and 
PIK3CA-GEMM mice developed HNSCC. The authentication of the PIK3CA tumors 
was validated by transgene-specific genotyping PCR (Figure 3.2G). By the time of 
tumor harvest, there were no differences in the general health and nutritional status 
(for example, activity or body weight) between the control mice and the PIK3CA 
GEMMs. 
 
Overexpression of PIK3CA in Murine Head and Neck Epithelia Promotes 
Tumor Invasion and Metastasis  
It was immediately clear that tumors from PIK3CA-GEMMs and those from 
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Figure 3.1. Generation and characterization of the inducible, head-and-
neck-specific PIK3CA genetically engineered mouse model (PIK3CA-
GEMM). (A.) Schematic of generating the PIK3CA-GEMM by breeding the 
transactivator mouse line K5.GLp65 to the target mouse line tata.PIK3CA. (B.) 
Fold inductions of the PIK3CA mRNA quantified by qRT–PCR using transgene-
specific primers. RU=RU486, n=6, *P<0.05. (C.) Western blot analysis on protein 
lysates from the buccal mucosa and tongue of the PIK3CA-GEMMs. (D.) 
Overexpression of PIK3CA resulted in epithelial hyperplasia in buccal mucosa 
and tongue from the PIK3CA-GEMMs. H&E staining of buccal mucosa and 
tongue from 7-month-old control mice and PIK3CA-GEMMs.Increased expression 
of p110α in the PIK3CA-GEMMs detected by IHC. Increased Ki-67 positive cells 
are evident in the buccal mucosa and tongue of the PIK3CA-GEMMs assessed 




papillomatous, tumors from the PIK3CA-GEMMs were flat (Figure 3.2C). 
Histologically, the majority of the control tumors had an out-growth pattern with intact 
basement membranes (Figure 3.2D and Figure 3.2H), whereas tumors from the 
PIK3CA-GEMMs predominantly had a down-growth pattern with broken basement 
membranes and invasion into muscle (right panels of Figure 3.2D and H). Although 
over 60% of the control tumors were well-differentiated or carcinoma in situ, over 
50% of the PIK3CA-overexpressing tumors were poorly differentiated as confirmed 
by a head and neck pathologist (Figure 3.2D, E and H). Notably, metastases were 
observed in ~40% of the PIK3CA-GEMMs (regional lymph node or lung metastases) 
compared with no metastases in control mice (Figure 3.2 and F). These data 
showed that overexpression of PIK3CA promoted 4NQO-induced HNSCC 
progression, particularly tumor invasion and metastasis. 
 
PIK3CA Overexpression Induced De-differentiation, EMT and Enriched CSC 
Properties 
The poorly differentiated tumor histology observed in the PIK3CA-GEMMs 
was further confirmed by immunostaining of several differentiation markers. As 
shown in Figure 3.3A, while Keratin 1 (K1, green) was still retained in the control 
tumors, marking well-differentiated SCC, it was lost in the PIK3CA-GEMM tumors. In 
contrast, Keratin 8 (K8, red), seen in poorly differentiated SCC, was rarely 
expressed in control tumors, whereas it was highly expressed in tumors from 
PIK3CA-GEMMs. This differential keratin expression was further confirmed by K and 
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Figure 3.2. Overexpression of PIK3CA together with 4NQO treatment 
increases tumor susceptibility and promotes tumor invasion and metastasis 
of the 4NQO-induced HNSCC . (A.) Schematics of the animal experiment. 
Starting at 1 month of age, PIK3CA-GEMMs and control mice were given 4NQO 
(50 μg/ml) in the drinking water for 16 weeks, and RU486 (β0 μg/mouse) applied 
orally twice weekly until harvesting mice at 12 months. (B.) Summary of tumor 
incidences in the PIK3CA-GEMMs and control mice. All mice underwent a 
biweekly full oral cavity examination, and any pathologic changes were 
documented. Tumor onset was significantly earlier for the PIK3CA-GEMMs (5–6 
months) than for the control mice. *P<0.01. (C.) Gross morphology of tongue 
SCCs from control mice (upper) and PIK3CA-GEMMs (lower). Dotted lines 
delineate the tumor boundary. Note that tumors from the control mice are 
papilloma-like, whereas those from the PIK3CA-GEMMs are flat. (D.) Hematoxylin 
and eosin (H&E) staining of representative tongue tumors shows that tumors from 
control mice have an out-growth pattern with intact basement membrane (upper 
left panel), and are well-differentiated (lower left panel), whereas tumors from the 
PIK3CA-GEMMs have a down-growth pattern, with invasion to the tongue muscle 
(upper right panel), and are poorly differentiated (lower right panel). Scale bar: 
100 μm for upper panel, and β5 μm for lower panel. (E.) Histopathological 
summary of oral tumors from control mice and PIK3CA-GEMMs. CIS, carcinoma 
in situ; Mod, moderately differentiated tumors; Poorly, poorly differentiated 
tumors; Well, well-differentiated tumors. (F.) H&E staining of representative lymph 
node and lung metastases. Dotted line delineates the upper boundary of the 
tumor. Scale bar: 100 μm. (G.) Validation of PIKγCA transgene in the tumors from 
the PIKγCA-GEMMs by PIKγCA-trangene specific PCR genotyping. Both 
K5.GLp65 and PIKγCA transgenes were present in the tumors from the PIKγCA-
GEMMs (lane 1-γ). Tumors from control mice (tata.PIKγCA, lane4; K5.GLp65, 
lane 6; wildtype, lane 5) contained either one or none of the transgenes. (H.) 
Histopathology of HNSCC tumors from control mice and PIKγCA-GEMMs. While 
the tongue tumors in the control mice are mostly carcinoma-in situ (top left panel) 
and well-differentiated tumors (middle and bottom left panels),  those from the 





to these findings, EMT was observed in the PIK3CA-GEMM tumors. As shown in 
Figure 3.3C, in contrast to the universal expression of the epithelial marker E-
cadherin (green) in control tumors, E-cadherin expression was lost in the PIK3CA-
GEMM tumors. Conversely, the mesenchymal marker Vimentin (red) was expressed 
only in the stroma of the control tumors, but was expressed in the epithelium of 
PIK3CA-GEMM tumors, suggesting that EMT had taken place. This was further 
confirmed by qPCR showing decreased E-cadharin and increased Vimentin mRNA 
expression in the PIK3CA-GEMM tumors (Figure 3.3D). Last, relative to controls, the 
PIK3CA-GEMM tumors showed significantly increased expression of several 
transcription factors regulating EMT, including Twist1, Zeb1, Zeb2 and Snail1 
(Figure 3.3E). Thus, the PIK3CA-GEMM tumors exhibited both histopathological and 
molecular signature of EMT. 
It has been shown that de-differentiation and EMT correlate with enhanced 
CSC/progenitor activity154. We thus examined putative CSC markers of HNSCC by 
qPCR. As shown in Figure 3.3F, overexpression of PIK3CA significantly increased 
the mRNA expression of CD44 and CD166, and reduced the expression of CD24, all 
of which indicate an enhanced CSC phenotype. This result is further supported by 
increased mRNA expression of embronic stem cell markers Nanog, Oct4 and EZH2. 
Interestingly, increased expression of Wnt5a, which is implicated in 
migration/invasion, was also found in the PIK3CA-GEMM tumors (Figure 3.3F). 
 
PIK3CA-GEMM Tumors Have Increased PDK1 Expression and Activation 






Figure 3.3. PIK3CA overexpression in tumor tissue promotes cellular de-
differentiation, epithelial-mesenchymal transition (EMT) and enrichment of 
cancer stem cell properties. (A.) Double immunofluorescence (IF) staining of 
keratin 1 (K1, green) and keratin 8 (K8, red) markers on tongue tumor samples 
from control mice and PIKγCA-GEMMs (n=7). K1 indicates well-differentiated 
cells, whereas K8 indicates poorly differentiated cells. Scale bar: β5 μm. (B.) 
Relative mRNA levels of K1 and K8 measured by qRT–PCR, normalized to -
actin. Results are averages of triplicate experiments. *P<0.05 (n=6 for each 
group). (C.) Double IF staining of epithelial marker E-cadherin (green) and 
mesenchymal marker Vimentin (red) on tongue tumor samples from control mice 
and PIKγCA-GEMMs (n=1β). Scale bar: β5 μm. (D.) Relative mRNA levels of E-
cadherin and Vimentin measured by qRT–PCR, normalized to -actin. Results 
are averages of triplicate experiments. *P<0.05 (n=6 for each group). (E.) 
Relative mRNA levels of EMT-related molecules measured by qRT–PCR, 
normalized to -actin. Results are averages of triplicate experiments. *P<0.05 
(n=6 for each group). (F.) Relative mRNA levels of putative markers for cancer 
stem cell of HNSCC (left panel) and molecules regulating CSC phenotype (right 
panel) measured by qRT–PCR. Results are averages of triplicate experiments. 





progression, we examined several key molecules in the PI3K pathway. It has been 
shown that the change of mRNA expression ratio between AKT1 and AKT2 
regulates EMT in breast cancer cells208. However, there were no significant changes 
of mRNA expression of AKT1, AKT2, PDK1 or PTEN in the PIK3CA-GEMM tumors 
compared with control tumors (Figure 3.4A). AKT1 and AKT2 protein levels were 
similar between control and PIK3CA-GEMM tumors. However, PDK1 protein levels 
were increased in PIK3CA-GEMM tumors (Figure 3.4I). We then examined AKT and 
PDK1 protein activation by western blotting. Surprisingly, we did not detect 
significant differences in AKT phosphorylation at either Ser473 or Thr308 between 
the control and the PIK3CA-GEMM tumors. However, PDK1 activation by 
phosphorylation at Ser241 was significantly enhanced in PIK3CA-GEMM tumors 
(Figure 3.4B). Similarly, immunohistochemistry (IHC) staining showed an increase of 
total PDK1 protein in the PIK3CA-GEMM tumors (Figure 3.4C). These findings were 
unexpected and suggested that PDK1 may mediate oncogenic signaling inPIK3CA-
driven HNSCC progression. Last, we examined several molecules that are 
commonly altered in human HNSCCs. 4NQO exposure causes the formation of DNA 
adducts, resulting in mutations207. We first examined two oncogenes that are 
commonly mutated in HNSCC, that is, Ras and PIK3CA. We sequenced eight 
PIK3CA-GEMM tumors and eight control tumors for mutations at codons 12, 13 and 
61 of the K-ras and H-ras genes, and exons 9 and 20 of the PIK3CA gene. The only 
mutation we found was a G to A point mutation in codon 12 of mouse K-ras gene, 
which changes glutamic acid to aspartic acid (Figure 3.4J). This mutation was found 




CyclinD1, K-ras, H-ras and N-ras in PIK3CA-GEMM and control tumors. We found 
increased Stat3 and decreased p16 mRNA in thePIK3CA-GEMM tumors compared 
with control tumors (Figure 3.4D). 
To further examine whether PDK1 is involved in the tumor progression of the 
PIK3CA-GEMM mice, we cultured primary tumor cells from both PIK3CA-GEMM 
tumors (CU110 cells) and control tumors (CUCON cells). As shown in the Figure 
3.4K-a, consistent with the EMT changes in the tumor tissues, CU110 cells were 
more spindle-like, whereas CUCON cells were more round and epithelial-like. 
Overexpression of p110α was observed in the CU110 cells compared with that in 
CUCON cells (Figure 3.6E, left panel). We then stalely knocked down PDK1 in the 
CU110 cells (CU110-shPDK1), along with CU110 cells with a scramble insert 
(CU110-SCR) as a control (Figure 3.4K-b). Knocking down PDK1 in the CU110 cells 
increased E-cadherin expression and decreased Vimention expression (Figure 
3.4E), but had no effects on phosphorylation of Smad2 or Smad3 (Figure 3.4K-b). In 
addition, knocking down PDK1 (CU110-shPDK1) significanly reduced cell 
proliferation compared to the control cells (CU110-SCR) (Figure 3.4F). Moreover, 
knocking down PDK1 in the CU110 cells moderately attenuated cell migration 
(Figure 3.4G) and invasion (Figure 3.4H) abilities. These data suggested that PDK1 
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Figure 3.4. Overexpression and activation of PDK1 but not AKT in PIK3CA-
GEMM tumors. (A.) Relative mRNA levels of PIKγCA, AKT1, AKTβ, PDK1 and 
PTEN measured by qRT–PCR. Results are averages of triplicate experiment. 
*P<0.05 (n=6 for each group). (B.) Western blotting analysis of tumor samples 
from control mice and PIKγCA-GEMMs using the antibodies as indicated. (C.) 
Immunohistochemistry (IHC) staining of p110α, pAKTser47γ and PDK1 in tumors 
from PIKγCA-GEMMs and control mice. Scale bar: 50 μm. (D.) qRT–PCR 
examination of mRNA levels of molecules commonly altered in human HNSCCs. 
Results are averages of triplicate experiments. *P<0.05 (n=6 for each group). (E.) 
Relative mRNA levels of PDK1, E-cadherin and Vimentin in CU110 cells with 
PDK1 knockdown (CU110-shPDK1) or with a scramble control (CU110-SCR) 
measured by qRT–PCR. *P<0.05. (F.) Cell proliferation assay of CU110-shPDK1 
and CU110-SCR measured by the Cell Counting Kit-8. *P<0.05. (G.) Migration 
assay in CU110-shPDK1 and CU110-SCR cells. Dotted line defines the edges of 
cells. All experiments were performed in triplicate. *P<0.05. (H.) Invasion assay in 
CU110-shPDK1 and CU110-SCR cells. All experiments were performed in 
triplicate. *P<0.05. (I.) Western blot analysis of AKT1, AKTβ, PDK1 and total AKT 
in tumors from PIKγCA-GEMMs and control mice. (J.) DNA sequencing results 
from a control tumor. The results showed a G to A mutation in codon 1β of the 
mouse K-ras gene, which changes glutamic acid to aspartic acid. (K.) a. Bright 
field images of cells cultured from either a control tumor (CUCON) or a PIK3CA-
GEMM tumor (CU110). b. Western blot analysis of PDK1, pSmad2, pSmad3 in 
the CU110-shPDK1 and the CU110-SCR cells. c. Cell proliferation assay in 
CU110 cells treated with TGF  type I receptor inhibitor, LYβ157β99 relative to a 




PIK3CA Overexpression Led to Increased Inflammation in HNSCC Tumor 
Stroma  
In addition to the de-differentiation and EMT changes in the PIK3CA-GEMM  
tumor cells, we observed numerous infiltrated leukocytes in the stroma of the 
PIK3CA-GEMM tumors on histological sections examined by hematoxylin and eosin 
staining (Figure 3.5C) and IHC with CD45 (Figure 3.5A). We then examined 
subtypes of infiltrated leukocytes using IHC. Tumor-associated macrophages are 
stained by F4/80 antibody, and myeloid-derived suppressor cells in a tumor 
microenvironment are stained by granulocyte markers Gr1 and CD11b209. Both cell 
types were increased in PIK3CA-GEMM tumors compared with control tumors 
(Figure 3.5A). Last, we evaluated which cancer-associated inflammatory cytokines 
were upregulated in PIK3CA-GEMM tumors. Among the 15 inflammatory 
chemokines/receptors we evaluated, mRNA levels of CCL3, CCR7, CXCL12 and 
CXCR4 were all significantly increased in the PIK3CA-GEMM tumors compared with 
the control tumors (Figure 3.5B). 
 
PIK3CA-GEMM Tumors Have Increased TGFβ1 Ligand, and Increased Smad3 
Expression and Activation  
The EMT change in tumor cells and the enhanced leukocyte infiltration in 
PIK3CA-GEMM tumors are similar to what we observed previously in HNSCC 
mouse models with aberrant TGF  signaling13,107,108. This prompted us to further 
investigate whether TGF  signaling contributes to PIKγCA-driven HNSCC 






Figure 3.5. Increased leukocyte infiltration and inflammation in tumors from 
PIK3CA-GEMMs.  (A.) Detection of leukocyte subtypes in tumors from PIK3CA-
GEMMs and control mice using IHC with CD45, F4/80, Gr1 and CD11b. Scale 
bar: 50 μm. (B.) qRT–PCR examination of inflammatory-related 
cytokines/chemokines and receptors. Results are averages of triplicate 
experiments. *P<0.05 (n=6 for each group). (C.) HE staining of PIKγCA-GEMM 





examine several TGF  signaling pathway molecules known to be altered in human 
cancers. We found that mRNA levels of TGF 1 and Smadγ were significantly higher 
in PIK3CA-GEMM tumor tissues than in control tumor tissues (Figure γ.6A). TGF 1 
protein level was also increased in the PIK3CA-GEMM tumor tissues, as determined 
by ELISA (Figure 3.6B). We then performed double IF of Smad3 and the epithelial 
marker E-cadherin. As shown in Figure 3.6C, the Smad3-positive area was inversely 
correlated with E-cadherin-positive staining, suggesting that Smad3 may contribute 
to the EMT changes in the PIK3CA-GEMM tumors. Increased phosphorylation of 
Smad3 in the PIK3CA-GEMM tumors compared with the control tumor tissues was 
also observed through western blot analysis (Figure 3.6D). 
To further assess the role of TGF  signaling in mediating the tumor-promoting 
effects of PIK3CA overexpression, we created CU110 cells in which the 
PIK3CAgene was knocked down (CU110-shPIK3CA), along with CU110 cells with a 
scramble insert (CU110-SCR) as a control (Figure 3.6E, right panel). To examine 
the effect of PIKγCA overexpression or knockdown on TGF  pathway in the cultured 
HNSCC cells to check whether PIK3CA-mediated regulation of TGF  pathway is cell 
autonomous in cancer cells, we compared TGF 1 mRNA levels in CUCON, CU110, 
CU110-shPIK3CA and CU110-SCR cells. As shown in Figure γ.6F, TGF  mRNA 
levels in the CU110 cells were about four times than that in the CUCON cells. 
Conversely, knocking down PIK3CA significantly reduced TGF 1 mRNA levels in 
CU110-shPIK3CA cells compared with the CU110-SCR cells, suggesting that the 
PIK3CA-mediated regulation of TGF  pathway is cell autonomous in cancer cells. 







Figure 3.6. Increased TGFβ ligand and smad3 expression and activation in 

















Figure 3.6. Increased TGFβ ligand and smad3 expression and activation in 
tumors from PIK3CA-GEMMs. (A.) qRT–PCR examination of molecules in the 
TGF  signaling pathway. *P<0.05 (n=6 for each group). (B.) ELISA quantification 
of TGF 1 ligand (n=5). (C.) Double IF staining of epithelial marker E-cadherin 
(green) and Smadγ (red). Note the inverse correlation between Smadγ and E-
cadherin in control and PIKγCA-GEMM tumors. (n=4), scale bar: β5 μm. (D.) 
Western blot analysis of phosphorylated Smadγ. (E.) Western blot analysis of 
p110α in cells cultured from a 4NQO-induced control tumor (CUCON) and a 
4NQO-induced PIKγCA-GEMM tumor (CU110), and CU110 cells with either a 
PIKγCA knockdown (shPIKγCA) or a scramble control (SCR). (F.) qRT–PCR 
examination of TGF 1 mRNA levels in CUCON and CU110 cells (left panel), and 
CU110 cells with PIKγCA knockdown (shPIKγCA) or scramble control (SCR; right 
panel). *P<0.05. (G.) Western blot analysis of phosphorylation of Smadβ and 
Smadγ in CU110 cells treated with a TGF  type I receptor inhibitor, LYβ157β99, 
or dimethyl sulfoxide (DMSO; control). (H.) Migration assay in CU110 cells treated 
with a TGF  type I receptor inhibitor, LYβ157β99, or DMSO (control). Dotted line 
defines the edges of cells. All experiments were performed in triplicate. *P<0.05. 
(I.) Invasion assay in CU110 cells treated with a TGF  type I receptor inhibitor, 





receptor kinase inhibitor, LYβ157β99, to address the contribution of TGF  pathway 
to the PIK3CA-driven HNSCC progression. Treatment with LY2157288 effectively 
reduced Smad2 and Smad3 phosphorylation, indicating the effectiveness of the 
inhibition of the TGF  signaling pathway (Figure 3.6G). Following the treatment, both 
cell migration and invasion were significantly hampered (Figure 3.6H and I), with a 
minor effect on cell proliferation (Figure 3.4K-c), indicating that the TGF  pathway 
contributes to migration and invasion of PIK3CA-driven HNSCC tumorigenesis. 
 
PIK3CA and PDK1 Are Associated with Progression in Human HNSCC 
To address the clinical relevance of our results from the PIK3CA-GEMM, we 
examined PIK3CA, PDK1 and pAKT expression levels in primary human HNSCC 
samples, case-matched adjacent mucosa and metastatic lesions, compared with 
normal oropharyngeal samples from patients with sleep apnea as controls. We first 
performed qRT–PCR to measure PIK3CA mRNA levels. Compared with normal 
controls, PIK3CA mRNA was increased in both adjacent mucosa and HNSCC 
samples (Figure 3.7A). Interestingly, increased PIK3CA expression positively 
correlated with reduced tumor differentiation and increased lymph node metastasis 
(Figure 3.7A). We then carried out IHC staining of p110α, PDK1 and pAKT. Figure 
3.7B summarizes the percentage of cases with immunostaining 2+ in HNSCC 
tumors and metastases. Consistent with PIK3CA qRT–PCR results, we found 
increased p110α immunostaining both in poorly differentiated HNSCCs and in 
metastases (Figure 3.7B and C). Interestingly, PDK1 expression positively 












Figure 3.7. PIK3CA, PDK1 and pAKT alterations in human HNSCCs. (A.) 
qRT–PCR quantitation of PIKγCA mRNA expression in human HNSCCs. Error 
bars indicate mean˃s.d. *P<0.05. Adj, adjacent mucosa; LN mets, lymph node 
metastases; Mod, moderately differentiated tumors; NN, normal controls; Poorly, 
poorly differentiated tumors; Well, well-differentiated tumors. (B.) Percentage of 
human HNSCC cases which exhibited greater than or equal toβ+ IHC staining of 
p110α, PDK1 and pAKT. *P<0.05. (C.) IHC staining of serial sections of a poorly 




However, AKT activation showed the opposite pattern, and demonstrated 
reduced expression in poorly differentiated tumors and metastases compared with 
early-stage lesions. These data from human tissue sample support our mouse 
model data that PIK3CA-driven HNSCC progression is predominantly mediated 




Previous mouse models were generated by knocking in PIK3CA mutant 
H1047into different tissue contexts210–214. However, somatic mutations ofPIK3CA are 
infrequent (~10%) compared with PIK3CA gene amplification (~40%) in HNSCC 
patients38,40. Thus, our PIK3CA-GEMM, in which the wild-type PIK3CA is 
overexpressed specifically in murine head and neck epithelium, more closely mimics 
the majority of human HNSCC patients. As this transgene can be induced in a 
spatio-temporal manner, our model is an ideal platform to assess the role of PIK3CA 
overexpression at each stage of HNSCC tumorigenesis. This also represents the 
first GEMM in head and neck tissue for studying the in vivo role of PIK3CA. 
In the PIK3CA-GEMM, we found that PIK3CA overexpression alone is not sufficient 
to initiate tumor formation in head and neck tissue. This is in contrast to the results 
of tumor formation in breast and lung cancer mouse models210–212. One explanation 
is that previous mouse models were based on gene mutations compared with our 
model, which is based on gene overexpression; these two types of gene alterations 




have a context-specific role in tumorigenesis. For example, the same mutant 
PIK3CA-H1047 that causes spontaneous breast and lung tumor formation is not 
sufficient to initiate tumor formation in ovarian or colon tissues unless coupled with 
either a PTEN or APC deletion213,214. Our data suggest that PIK3CA overexpression 
may not initiate tumorigenesis, but instead it promotes tumor progression in HNSCC. 
Compared with the well-documented mitogenic signaling of PI3K in cell 
growth and survival, the role of PI3K in tumor invasion and metastasis has not been 
well delineated. In a subset of aggressive breast cancer, which exhibits EMT and 
CSC characteristics, the authors found the mutation rate of PIK3CA reached nearly 
50%, significantly higher than in any other types of breast cancer215. Knocking in the 
PIK3CA mutant into a breast cancer cell line also resulted in an EMT phenotype216. 
In line with these data, our PIK3CA-GEMM provides the first in vivo evidence that 
PIK3CA alteration is able to drive tumor progression at least partially through 
enriched EMT and CSC characteristics, which may be responsible for the invasive 
and metastatic phenotype observed in the PIK3CA-GEMM. 
AKT is largely regarded as the dominant mediator of oncogenic PI3K 
signaling38. However, studies suggest that the link between PI3K and AKT can be 
uncoupled41–44. Recent reports showed that AKT can directly phosphorylate Twist1 
to promote EMT217, and that the ratio of AKT1 and AKT2 and its regulated 
microRNAs are responsible for EMT and CSCs208. However, we found no 
differences in AKT activation or expression of AKT isoforms between control 
andPIK3CA-GEMM tumors. Lack of AKT activation has also been observed in 




initiated melanoma205. AKT activation can be detected in mouse models as early as 
pre-neoplastic lesions upon either 4NQO219 or NNK treatment122 and AKT activation 
in the oral cavity can initiate benign tumor formation. However, it fails to promote 
tumor progression unless combined with p53 loss suggesting that AKT activation 
may be involved in early events in HNSCC carcinogenesis, but not in tumor 
progression. In some breast cancers with PIK3CA mutations, PDK1, but not AKT, is 
activated42. Similarly, our results suggest that PDK1, rather than AKT, facilitates 
progression of PI3K-driven HNSCC, which raises the possibility of PDK1 as a 
therapeutic target in HNSCC patients with PIK3CA alterations. 
PDK1 is a serine/threonine protein kinase that phosphorylates members of 
the AGC kinase superfamily, including AKT, and is implicated in cell proliferation, 
survival and metabolism220. Interestingly, PDK1 has been shown to regulate cell 
migration but not proliferation in lymphocytes92 and to promote EMT in cardiac 
development93. Compared with the extensive research into AKT, less is known about 
the role of PDK1 in human cancers. Overexpression of PDK1 has been reported in 
several human cancers94,96,221 and correlates with disease progression in patients 
with pancreatic cancer or melanoma96,221. Interestingly, PDK1 is required for Kras-
driven pancreatic cancer in murine models but not for the Kras-driven lung cancer, 
suggesting a context-specific role of PDK195. In HNSCC, PDK1 has been shown to 
mediate G-protein-coupled receptor and epidermal growth factor receptor (EGFR) 
cross-talk as well as cell growth, both in vitro and in vivo222. It has become evident 
recently that the role of PDK1 in physiological and pathological conditions is not 




example, PDK1 has been shown to activate SGK3 in a PI3K-dependent, AKT-
independent manner in breast cancer42. PDK1 can also directly activate PLC 1 to 
mediate cancer cell invasion223. Moreover, PDK1 directly phosphorylates polo-like 
kinase 1 to induce an embryonic stem cell-like gene signature associated with 
aggressive tumor behaviors and CSC self-renewal224. Further investigation on the 
downstream molecular mechanisms underlying PI3K/PDK1 signaling in the PIK3CA-
GEMM will provide important insights into PIK3CA-driven HNSCC progression and 
identify novel therapeutic targets to control HNSCC progression. 
The downstream mechanisms of PI3K/PDK1 in HNSCC invasion and 
metastasis are largely unknown. In this study, we found that the TGF 1 ligand and 
its downstream mediator Smad3 are overexpressed in PIK3CA-GEMM tumor 
tissues. The positive correlation between PIKγCA and TGF 1 levels was further 
detected in both PIK3CA-overexpressing tumor cells and PIK3CA-knockdown tumor 
cells, suggesting that the PIK3CA-mediated regulation of TGF  pathway is cell 
autonomous. The contribution of TGF  pathway to mediate migration and invasion 
of PIK3CA-overexpressing tumor cells was validated by treating these cells with a 
TGF  pathway inhibitor. Cross talk between PIγK and TGF  signaling can occur at 
multiple levels102. For example, PI3K is able to mediate TGF -receptor-initiated 
intracellular signaling225. In addition, PI3K can antagonize TGF -induced cytostasis 
and cause the shift in TGF  signaling to tumor progression102. However, prior 
reports on PIγK and TGF  interplay were almost exclusively related to AKT 
signaling102. Thus, it remains unclear how PIγK/PDK1 interacts with TGF /Smadγ 




Currently, the only Food and Drug Administration-approved targeted therapy 
for HNSCC is EGFR inhibitors33. Targeting the PI3K pathway represents a promising 
new strategy for treating HNSCC. The role of PDK1 in mediating invasion and 
metastasis of PIK3CA-driven HNSCC suggests it may be useful as a therapeutic 
target. Targeting PDK1 using either genetic approaches or pharmaceutical inhibitors 
has been shown to inhibit CSC self-renewal and metastasis96,224,226. In one pre-
clinical study on HNSCC, PDK1 inhibition showed anti-tumor effects either by itself 
or in combination with EGFR inhibition222. Thus, targeting PIK3CA or PDK1 presents 
an important new avenue for HNSCC treatment. Targeting TGF  as anti-cancer 
therapy has been evaluated for a decade in multiple cancers227. However, it remains 
unclear how it may best be used and such therapies are highly stage- and patient-
specific. The possible synergistic role of over-activated PIγK and TGF  signaling in 
HNSCC progression demonstrated in this study has prompted testing of combination 
therapy. If proven effective in pre-clinical trials with PIK3CA-GEMM, this combination 
therapy will be immediately translated into clinical trials for treating advanced 
HNSCC patients who have PIK3CA alterations. 
In summary, we report a GEMM in which the PIK3CA is overexpressed in  
head and neck epithelia. Although overexpression of PIK3CA alone is not sufficient 
to initiate HNSCC formation, it significantly increased the susceptibility to the 4NQO-
induced HNSCC carcinogenesis. More importantly, PIK3CA overexpression 
promotes EMT and CSC properties and drives tumor invasion and metastasis, which 
is likely mediated by increased PDK1 expression and activation, and subsequently 




foundation for future investigations into the mechanism of PDK1 and its interplay 
with TGF  signaling in PIKγCA-driven HNSCC tumorigenesis. Moreover, it suggests 
that therapeutic targeting of PDK1 and/or TGF  signaling may effectively control 




















DISTINCT ROLES OF PIK3CA IN ENRICHING AND MAINTAINING OF CANCER 
STEM CEELS IN HNSCC 
 
Introduction 
Head and neck squamous cell carcinoma (HNSCC) accounts for 
approximately 6% of all cancer cases and is the sixth most common cancer 
worldwide203,204. The overall 5-year survival rate of HNSCC is 40-50%, and has not 
been significantly improved over  the past several decades38,40,204. The main reasons 
for the poor prognosis of HNSCC patients are loco-regional invasions, recurrence, 
and distant metastasis3–5. On initial presentation, ~10% of HNSCC cases show 
metastases and the survival rate for these patients is less than 1 year228. 
Additionally, ~30-40% of post-treated HNSCC patients develop recurrence or 
metastasis228. Thus, therapies controlling HNSCC recurrence and/or metastasis are 
pivotal to improve poor survival of HNSCC patients.  
The phosphatidylinositol 3-kinase (PI3K) signaling pathway is the most 
frequently altered oncogenic pathway in HNSCCs16,17,46. Recent whole-exome 
sequencing of HNSCC samples has identified mutations (10%) and/or amplification 
(40%) of PIKγCA, the gene encoding for p110α subunit of PIγK, making it the most 
common altered oncogene in human HNSCC patients16,17,38,40,46,48. To better 
understand the role of PIK3CA in the development and progression of HNSCC in 
vivo, in last chapter, we overexpressed PIK3CA in the head-and-neck epithelium 




(GEMM)14. We showed that while overexpression of PIK3CA was not sufficient to 
initiate tumorigenesis, it markedly promoted HNSCC progression manifested as 
poorly-differentiated, metastatic tumors with a phenotype of epithelial-to-
mesenchymal transition (EMT) and increased gene expression related to head and 
neck cancer stem cells (CSCs). This data suggest that EMT and CSC traits may 
drive tumor invasion and metastasis in HNSCC patients with PIK3CA amplification.  
EMT is a process by which epithelial cells lose their cell polarity and cell-cell 
adhesion, and gain migratory and invasive properties to become mesenchymal 
cells131. CSCs refer to a subset of cancer cells that possess the pluripotent 
characteristics, such as self-renewal or regeneration of normal stem cells. Cancer 
cells can hijack EMT program to become more migratory, invasive, resistant to 
anoikis/chemotherapies, or gain CSC properties, in which all these EMT characters 
can contribute to cancer progression137,154,229. In general, CSCs are intend to be 
quiescent, Since CSCs possess self-renewal and tumorigenic properties, and are in 
general quiescent and required less nutrients, it is believed that they are more 
suitable to survive in a harsh environment, resistant to chemo-radiation therapies, 
and can be “seeds” for tumor formation either primarily (tumor initiation), secondarily 
(recurrence), or distantly (metastasis)136,137.  
To further understand the role of EMT and CSCs traits in HNSCC 
progression,  in this chapter, we further investigate these two processes using both 
murine HNSCC cells isolated from the PIK3CA-GEMM I presented in last chapter, 
and human HNSCC cell lines with PIK3CA genetic alterations. Our data revealed 




murine and human HNSCC cell lines. Surprisingly, inhibition of PIK3CA or key 
components in the PI3K pathway failed to reduce, but rather promote CSC 
population. To reveal the molecular mechanism of this PI3K-independent CSC 
phenotype, we performed a receptor tyrosine kinase (RTK) array, and found that 
multiple RTKs were activated in the PIK3CA-overexpressing HNSCCs. 
Pharmaceutical inhibitor screening showed the effectiveness of targeting Ephrin 
receptors (Ephs) or tropomyosin receptor kinases (Trks) in reducing CSC 




Overexpression of PIK3CA Promotes Cell Proliferation, Migration, Epithelial-
to-mesenchymal T ransition and De-defferentiation 
We have recently reported a genetically engineered mouse model (GEMM) in 
which the PIK3CA transgene is overexpressed in murine head and neck epithelia. 
Although overexpression of PIK3CA alone is not sufficient for HNSCC development; 
it significantly promotes HNSCC invasion and metastasis. Epithelial-to-mesenchymal 
transition (EMT) and enriched cancer stem cell phenotype were observed in the 
PIK3CA-overexpressing HNSCC tumors compared to the 4-NQO induced control 
HNSCC tumors14. To further investigate the molecular mechanisms underlying the 
PIK3CA-driven HNSCC progression, we established primary murine HNSCC cell 
lines from two individual PIK3CA-overexpressing HNSCC tumors (Hereafter referred 




tumors (Hereafter referred to as CUCON-1 and CUCON-2). (Figure 4.1A).  As 
shown in the Figure 4.1A, consistent with the EMT changes in the tumor tissues, 
CU110 cells were more spindle-like, while CUCON cells were more round and 
epithelial-like. The authentication of these cell lines was validated by the transgene-
specific genotyping PCR. As anticipated, the resulting CU110 cells showed higher 
expression of p110α and enhanced phospho-AKT level compared with CUCON cells 
(Figure 4.1B), indicating that PI3K/AKT signaling is highly active in the cell lines 
established from tumors of PIK3CA-GEMM. Accompanying with the elevated 
PI3K/AKT signaling, CU110 cells also displayed higher proliferative and migratory 
capacities compared with CUCON cells (Figures 4.1C and D). 
We further characterized EMT phenotype as we observed in the tumor 
tissues and the cell morphologies of control and PIK3CA-overexpressing HNSCCs. 
Western blotting results showed that overexpression of PIK3CA in CU110 cells 
promotes EMT shown as loss of the epithelial marker, E-cadherin and increase 
expression of the mesenchymal marker, Vimenten (Figure 4.2A). 
Immunofluorescence staining for E-cadherin and Vimentin further confirmed EMT 
phenotype in CU110 cells compared to CUCON cells (Figure 4.2B).  Next, we 
analyzed expression of various transcription factors known to regulate EMT program 
by using quantitative RT-PCR. We found that Zeb1, Twist 1, Snail1 and Ets1 
expression but not that of Twist2 and Snail 2, was significantly higher in CU110 cells 
compared to CUCON cells (Figure 4.2C). As the EMT process generates poorly 
differentiated tumor cells that are defined by losing cytokeratins230, we further 









Figure 4.1. Overexpression of PIK3CA promotes cell proliferation and 
migration (A.)  Culture of murine HNSCC cells from either 4NQO-induced tumors 
or PIK3CA-overexpressing tumors. Left: H&E staining of tumor samples; Right: 
phase contrast images of CUCON and CU110 cells. (B.) Western blotting of 
p110a in murine CUCON and CU110 cells. GAPDH was used as a loading 
control. (C.) Cell proliferation assay quantified by Vi-cell viability analyzer 
(Beckman Coulter). Cells were initially seeding as  equal numbers and were 
quantifying live cell number at day 1, day 3, day 6 and day 8 (D.) Wound healing 
assays for CU110 and CUCON cells. For each assay, 3 individual experiments 
were performed; distance migrated was measured on the picture taken on day 1 




Here we found that expression of several cytokeratins was significantly decreased in 
CU110 cells compared to the CUCON cells (Figure 4.2D), suggesting that CU110 
cells are poorly differentiated.  Together, these data demonstrate that 
overexpression of PIK3CA promotes cellular proliferation, migration, EMT, and de-
differentiation. 
 
Overexpression of PIK3CA Enriches Putative Head and Neck Cancer Stem 
Cells  
It has been shown that EMT and de-differentiation generate cells possessing 
properties of stem cells and confer cancer cells with stem cell-like characteristics154. 
To examine if the EMT and de-differentiation phenotypes of CU110 cells generate 
more cancer stem cells (CSCs), we utilized several putative surface markers 
reported for CSC isolation in HNSCC. CD44 and CD24 have been widely used 
individually or in combination to isolate CSCs from several solid tumors231,232,  
including HNSCC142,144. As shown in Figure 4.3A, FACS results showed significantly 
higher numbers of CD44+ and lower number of CD24+ cells in CU110 cells 
compared to CUCON cells. Side population (SP) as measurement of Hoechst dye 
effluxing activities and aldehyde dehydrogenase (ALDH) activity were also used for 
isolating CSCs in several solid tumors, including HNSCC145,146. As shown in Figure 
4.3B, about 1.4% of SP cells were identified in the CU110 cells, whereas no SP cells 
were identified in the CUCON cells. The specificity of SP cells was further validated 
by verapamil elimination experiment.  Similarly, a moderate increase of ALDH 









Figure 4.2. Overexpression of PIK3CA promotes epithelial to mesenchymal 
transition and de-differentiation. (A.)  Western blotting of E-cadherin and 
Vimentin in CUCON and CU110 cells. GAPDH was used as a loading control. 
(B.) Immunofluorescence staining of of E-cadherin (Green) and Vimentin (Red) in 
CUCON and CU110 cell lines. DAPI stain (Blue) was used to visualize the 
nucleus. (C.) qRT-PCR analysis of transcriptional factors regulating EMT. Fold 
changes are relative to CUCON-1 cells. (D.) qRT-PCR analysis of cytokeratins in 




Together, these data showed that overexpression of PIK3CA enriches putative 
CSCs in HNSCC. 
 
Sphere Forming Capacity is a Functional Measurement for Cancer Stemness 
Properties of HNSCC 
To determine if the enriched CSC-like population of CU110 cells exhibits 
efficient self-renewing capacity, we evaluated the sphere-forming capacities of 
CU110 and CUCON to assess the self-renewal ability of CSCs147. Consistent with 
the enrichment of CSCs in CU110 cells, the CU110 cells, but not CUCON cells  
were able to form spheres in ultralow-attachment, serum-free condition (Figure 
4.4.1A). To further examine if the spheres possess CSC properties, we measured 
mRNA expression of embryonic stem cell markers Nanog, Oct4, and Sox2. As 
shown in Figure 4.4.1B, expression of these markers were significantly increased in 
spheres compare to monolayer cultured CU110 cells. We further performed 
hematoxylin and eosin (H&E) staining on sections of spheroids and observed 
distinguishable layers with a hollow center. Moreover, the middle and inner layers of 
these spheroids featured intensive extracellular matrix (Figure 4.4.2A). In consistent 
with higher mRNA expression of Sox2 in spheroids, the outer layer contained many 
SOX2+ cells observed by immunofluorescence (Figure 4.4.2B). However, not all 
CD44+ cells were SOX2+ (Figure 4.4.2B, lower panel). Moreover, some SOX2+ 
cells were Ki67+ (Figure 4.4.2B, top panel), suggesting that not all CSCs are 
quiescent and some maybe highly proliferative, questioning if quiescence or slow-








Figure 4.3. Overexpression of PIK3CA enriches putative head and neck 
cancer stem cell population. (A.)  FACS analysis of cell surface marker, CD44 
and CD24 in CUCON and CU110 cells. Quantification data are represented as 
mean ± SD. (B.) Side population (SP) fraction detected by Hoechst dye-effluxing 
assay of CUCON and CU110 cells. Left panel: representative FACS plots of 
CUCON and CU110 cells treated with Hoechst33342 in the presence and 
absence of verapamil. Right panel: quantification of gated SPs of CUCON and 
CU110 cells.  (C.) ALDH activity assay using Aldefluor staining and quantification 





were also CD34+ or CD133+ (Figure 4.4.2C). In addition, almost all outer-layer cells 
were Vimentin+ and K1+, and cells near the hollow center showed caspase 3 
positive staining, suggesting that these cells were undergoing apoptosis (Figure 
4.4.2C).  
To evaluate tumorigenicity of spheral cells in vivo, we injected 105 and 103 
cells from either sphere-, or monolayer- cultured CU110 cells into the flanks of 
syngeneic BL6 mice. While both sphere- and monolayer- cultured CU110 cells 
generated tumors at similar kinetics, and sizes of all mice injected, cells from 
spheres developed larger tumors in all mice injected compared to only one mouse 
developed smaller tumor after injection of monolayer-cultured CU110 cells. The 
average volumes of tumors from sphere was about 7-fold higher than that from the 
tumor of monolayer cells (Figure 4.4.3A). Last, we investigated whether sphere 
forming ability is correlated with p110α expression in human HNSCC cell lines. 
Among the 17 human HNSCC cell lines we screened, the sphere-forming ability was 
found to be well correlated with p110a expression levels, suggesting that 
overexpression of PIK3CA enriches CSC population in human HNSCC (Figure 
4.4.3B). 
 
Knockingdown PI3K Failed to Reverse EMT Phenotype and Reduce CSC 
Population 
Next, we examined whether PIK3CA is required for maintaining EMT 
phenotype and CSC population in the PIK3CA-overexpressing CU110 cells. We 







Figure 4.4.1. Sphere forming capacity is a functional measurement for 
cancer stemness properties of HNSCC.  (A.) HNSCC sphere-forming ability of 
two CUCON and two CU110 cells. Left panel: phase contrast images of CUCON 
and CU110 cells in serum-free and ultralow attachment culture condition. Right 
panel: quantification of sphere numbers for two CUCON and two CU110 cells. 
Spheres with diameter ≥ γ0 microns were counted.  (B.) qRT-PCR for expression 
of embryonic stem cell genes in the monolayer- or sphere-cultured CU110 cells.  







Figure 4.4.2. Sphere forming capacity is a functional measurement for CSC-
like properties of HNSCC.  (A.) H&E staining for HNSCC sphere section. (B.) 
Immunofluorescence staining on sphere section using the antibodies as indicated 
in figures. (C.) Immunofluorescence staining on sphere sections using the 
antibodies as indicated in figures. K8 or Vimentin positive layer was delineated by 
white dotted lines in middle panel (right) and lower panel (left); hollow center 






Figure 4.4.3. Sphere forming capacity is a functional measurement for 
cancer stemness properties of HNSCC.  (A.) In vivo tumorigenicity by 
subcutaneously injection of either sphere-or monolayer cultured CU110 cells to 
the flanks of BL6 mice. Upper: tumor incidence of monolayer- or sphere- cultured 
CU110 cells. Lower: left: Images of tumors developed from monolayer or sphere-
cultured CU110 cells. Right: quantification of tumor volume. **, p  0.01.  (B.) 
Correlation between p110a expression and sphere-forming ability in human 
HNSCC cell lines. Left panel: Western blotting and HNSCC sphere forming assay 
were performed in 17 human head and neck cancer cell lines 
(UMSCC1/2/10A/10B/22A/22B/47, VU1131/1365, SCC9, Fadu, HN6, Tu, Cal27, 
M4C/4E and LNM1). Relative quantification of p110a was done by quantifying 
band intensity of p110a and GAPDH, and is shown as percentage of GAPDH 
band intensity.  **, p  0.01. Right panel: representative images of sphere-forming 
capacity of HNSCC cell lines in serum-free and ultralow attachment culture 




PIK3CA. Surprisingly, knocking down of PIK3CA failed to induce E-cadherin or 
reduce Vimentin expression as shown by Western and IF staining (Figure 4.5.1A 
and B), indicating PIK3CA is not required for maintaining the EMT phenotype in 
PIK3CA-overexpressing cells.   We further examined the effects of knocking down 
PIK3CA on CSC phenotype in CU110 cells. As shown in Figure 4.5.1C to E, instead 
of reducing CSC population, knocking down of PIK3CA unexpectedly promoted CSC 
population in CU110 cells.  In the HNC sphere assay, knocking down of PIK3CA 
moderately increased HNC sphere numbers (Figure 4.5.1C).  In the CSC cell 
surface marker assays, while knocking down of PIK3CA had no effects on CD44+ 
population, it significantly increased and CD24- populations (Figure 4.5.1D).  
Furthermore, PIK3CA knockingdown caused about 5-fold increase in side population 
(Figure 4.5.1E).   
We further examined effects of knocking down PIK3CA in two human HNSCC 
cell lines, Fadu and UMSCC47 (Figure 4.5.2B). The Fadu cell line contains a gain-of 
function mutation of PIK3CA233, and was originated from a HPV negative HNSCC 
patient. The UMSCC47 cell line overexpresses PIK3CA the most among 8 HNSCC 
cell lines we screened (Figure 4.5.2A), and it was originated from a HPV positive 
HNSCC patient. Knocking down PIK3CA in either Fadu or UMSCC47 cell lines 
reduced cell proliferation and migration (Figure 4.5.2C and D). However, similar to 
the effect we observed in the murine CU110 cells, knocking down PIK3CA failed to 









Figure 4.5.1. Knocking down PIK3CA failed to revers e EMT phenotype and 

















Figure 4.5.1. Knocking down PIK3CA failed to revers e EMT phenotype and 
reduce CSC population .  (A.) Western Blot of p110α, E-cadherin, and vimentin 
in CU110-2 cells stably transfected lentiviral-mediated shRNA (shPIK3CA) or a 
scrambled control (SCR). GAPDH was used as a loading control. (B.) 
Immunofluorescence staining of E-cadherin or Vimentin in CU110-2 cells stably 
transfected with either sh-PIK3CA or a scrambled control (SCR). DIPI staining 
(blue) was used to visualize the nucleus. (C.) HNSCC sphere-forming assay of 
CU110 cells stably transfected either shPIK3CA or SCR lentivirus. Spheres with 
diameter ≥ γ0 microns were counted; Quantification of sphere is shown in right, 
n=3; error bars indicate SD. (D.) FACS analysis of CD44 and CD24 in CU110 
cells stably transfected either shPIK3CA or SCR lentivirus. Quantification of CD44 
ad CD24 population is shown in right. n=3; error bars indicates SD. (E.) Side 
population fraction using Hoechst dye-effluxing analysis in CU110 cells stably 
transfected either shPIK3CA or SCR lentivirus. Quantification of SP fraction is 






Figure 4.5.2. Knocking down PIK3CA reduced cell proliferation and 





















Figure 4.5.2. Knocking down PIK3CA reduced cell proliferation and 
migration, but not CSC population in human HNSCC cell lines. (A.) 
Screening of PIK3CA expression in 8 human head and neck cancer cell lines (as 
indicated) by using qRT-PCR. (B.) Western blotting in Fadu (left) and UMSCC47 
cell lines (right) stably transfected with either lentiviral - mediated short hairpin sh-
PIK3CA or scramble control (SCR). (C.) Cell proliferation assay of Fadu (left) or 
UMSCC47 (right) cell lines stably transfected with either sh-PIK3CA or scramble 
control (D.) Cell migration assay of Fadu  or UMSCC47 cell lines stably 
transfected with either sh-PIK3CA or scramble control. (E.) HNSCC sphere 
forming assay of Fadu or UMSCC47 cell lines stably transfected with either sh-
PIK3CA or scramble control (SCR). The quantification is shown in right. n=3; 




Knocking Down Key Components in PI3K Pathway Promotes CSC Population  
The effect on CSC population upon PIK3CA knocking down is unexpected, 
and promoted us to examine this effect upon knock down other key components in 
PI3K pathway. We first examined the expression levels of several PI3K isoforms in 
PIK3CA-overexpressing cells. As shown in Figure 4.5.3 A and B, PIK3R1, the gene 
encoding for the p85α adaptor protein of PIγK, is concurrently highly expressed in 
CU110 cells as measured by qRT-PCR and Western blotting. Interestingly, the level 
of p85a is also correlated with the abilities of sphere forming in human HNSCC cell 
lines (Figure 4.5.3C). We then stably knocked down PIK3R1 in CU110 cells. Similar 
to the effect of knocking down PIK3CA, PIK3R1 knock down had no effect on 
reverse EMT shown as qRT-PCR analysis on E-cadherin, Vimentin and several 
transcriptional factors regulating EMT (Figure 4.5.4A and B). Knocking down PIK3R1 
also failed to reduce CSC population as shown by HNSCC sphere forming assay 
(Figure 4.5.4C), FACS analysis of surface markers CD44, and CD24 (Figure 
4.5.4D), and SP fraction (Figure 4.5.4E). Instead, similar to PIK3CA knocking down, 
knocking down PIK3R1 promoted CSC population (Figure 4.5.4C to E). 
It has been reported that the ratio of AKT1 and AKT2 expression regulates 
EMT and CSC properties in a breast cancer model208. Thus, we further knocked 
down AKT1 or AKT2 in the CU110 cells (Figure 4.5.5A). Similar to the effects of 
PIK3CA or PIK3R1 knock down, AKT1 or AKT2 knocking down had no effects on 
EMT as shown by qRT-PCR of E-cadherin, Vimentin and several transcriptional 
factors regulating EMT (Figure 4.5.5B).  Knock down either AKT1 or AKT2 also 




(Figure 4.5.5C), FACS analysis of surface markers CD44 and CD24 (Figure 4.5.5D), 
and SP fraction (Figure 4.5.5 E). 
Last, we have recently showed that PDK1 contributes to tumor progression in 
the PIK3CA-GEMM study as evidenced by reduced proliferation, migration and 
reverse EMT upon PDK1 knocking down14. However, knocking down PDK1 had no 
effect on HNSCC sphere forming abilities, on putative CSC surface markers CD44 
and CD24 (Figure 4.5.6A and B), and increases SP fraction in the PIK3CA-
overexpressing cells (Figures 4.5.6C). 
 
Targeting Multiple Receptor Tyrosine Kinase Pathways Effectively Eliminates 
CSC Populations with Inhibiting Ephs, Trks and c-kit the Most Prominent 
Since the maintenance of PIK3CA overexpression-induced CSC properties is 
no longer dependent on PI3K signaling, we sought to identify other mechanisms 
important for maintaining the CSC phenotype. We thus performed a receptor 
tyrosine kinase protein array to compare the differences between the PIK3CA-
overexpressing cells (CU110) and the control cells (CUCON). As shown in Figure 
4.6A, compared to CUCON cells, there were multiple activated RTKs in CU110 cells, 
i.e. EGFR, FGFRs, InsR, TrkA and B, c-Kit, Ephrin receptors, Tyro3, Axl, VEGFRs, 
S6 ribosomal protein, and AKT. We further examined the RTK profiles of inhibition of 
PI3K pathway either by genetic knocking down of PIK3CA or using PI3K inhibitor 
PX866. Our results showed that there were in general no changes of RTK profiles 
upon these two conditions, suggesting these activated multiple RTKs are not 







Figure 4.5.3. Examination of PI3K isoforms in murine HNSCC cells. (A.) qRT-
PCR results of PI3K isoforms in two CUCON and two CU110 cells. Fold changes 
are relative to CUCON-1 cells; GAPDH was used as an internal control and 
results indicate means of triplicate experiments. Results of PIK3CG, PIK3C2A 
and PIK3C3 are not shown due to no amplification in both CUCON ad CU110 
cells. (B.) Western blotting of p110α and p85α in two CUCON and two CU110 
cells. GAPDH was used as a loading control. (C.) Correlation between p85α 
protein and sphere-forming ability in human HNSCC cell lines.  Western blotting 
and HNSCC sphere forming assay were performed in 12 human head and neck 
cancer cell lines (VU1131, VU1365, UMSCC1, UMSCC2, UMSCC47, Fadu, Tu, 
HN6, LNM1, CAL27, M4C, and M4E). Relative quantification of p85α was done 
by quantifying band intensity of p85α and GAPDH, and is shown as percentage of 







Figure 4.5.4. Knocking down PIK3R1 failed to reverse EMT but promoted 




















Figure 4.5.4. Knocking down PIK3R1 failed to reverse EMT but promoted 
CSC population. (A.) Western blotting in CU110 cells stably transfected with 
either lentiviral - mediated short hairpin sh-PIK3R1 or scramble control (SCR). 
GAPDH was used as a loading control. (B.) qRT-PCR results of E-cadherin, 
vimentin and EMT-related transcription factors in CU110 cells stably transfected 
with either sh-PIK3R1 or SCR lentivirus. (C.) HNSCC sphere forming assay of 
CU110 cells stably transfected with either sh-PIK3R1 or SCR lentivirus. The 
quantification is shown in right. Spheres with diameter ≥ γ0 microns were 
counted. n=3; error bars indicate SD. (D.) FACS analysis of CD44 and CD24 
population in CU110 cells stably transfected with either sh-PIK3R1 or SCR 
lentivirus. (E.)  Side population (SP) fraction using Hoechst dye-effluxing analysis 
in CU110 cells stably transfected either shPIK3R1 or SCR lentivirus. 







Figure 4.5.5. Knocking down AKT1 or AKT2 failed to reverse EMT but 












Figure 4.5.5. Knocking down AKT1 or AKT2 failed to reverse EMT but 
promoted CSC population. (A.)  Western blotting of CU110 cells stably 
transfected with either lentiviral -mediated short hairpin sh-AKT1, AKT2 or 
scramble control (SCR). GAPDH was used as a loading control. (B.) qRT-PCR 
results of E-cadherin, vimentin and EMT-related transcription factors in CU110 
cells stably transfected with either sh-AKT1, sh-AKT2 or SCR lentivirus. (C.) 
HNSCC sphere forming assay of CU110 cells stably transfected with sh-AKT1, 
sh-AKT2 or SCR lentivirus. The quantification is shown in right. Spheres with 
diameter ≥ γ0 microns were counted. n=γ; error bars indicate SD. (D.) FACS 
analysis of CD44 and CD24 population in CU110 cells stably transfected with 
either sh-AKT1, sh-AKT2 or SCR lentivirus. (E.) Side population (SP) fraction 
using Hoechst dye-effluxing analysis in CU110 cells stably transfected sh-AKT1, 








Figure 4.5.6. Knocking down PDK1 promoted CSC population. (A.) HNSCC 
sphere forming assay of CU110 cells stably transfected with either lentiviral-
mediated short hairpin sh-PDK1 or scramble control (SCR). The quantification is 
shown in right. Spheres with diameter ≥ γ0 microns were counted. n=γ; error bars 
indicate SD. (B.) FACS analysis of CD44 and CD24 population in CU110 cells 
stably transfected with either sh-PDK1 or SCR lentivirus. (C.) Side population 
(SP) fraction using Hoechst dye-effluxing analysis in CU110 cells stably 





To identify key pathway(s) regulating CSC phenotype, we utilized a 
pharmaceutical inhibitor screen approach to assess their effects on inhibiting 
HNSCC sphere forming. We selected inhibitors targeting the activated RTK 
pathways from the RTK protein array experiment described above. In addition, to 
evaluate the effects of targeting PDK1 and TGF  signaling, two targets we have 
recently reported which contribute to PIK3CA-overexpressing driven HNSCC 
progression14, we included inhibitors targeting PDK1, i.e.,GSK2334470 and TGF  
type I receptor i.e., LY2157299. Furthermore, chemotherapy drug Paclitaxel was 
also included to assess its effects on HNSCC sphere forming ability (Table 4.1). As 
shown in Figure 4.7.1A, while PX866 increased the numbers of HNSCC spheres, 
inhibitors targeting Ephrin receptors (LDN211904), Trk/B (GNF5837), and c-kit 
(Imatinib) effectively reduced or eliminated HNSCC sphere formation. In addition, 
treating CU110 cell by LDN211904 also reduced CD44+, and ALDH+ populations 
(Figure 4.7.1B), treating CU110 cell by GNF5837 significantly reduced ALDH+ 
population (Figure 4.7.1C), and treating CU110 by Imatinib reduced CD44+ 
population and SP+ fraction (Figure 4.7.1D).  
The attenuation of CSC phenotype upon inhibition of Ephs, Trks and c-kit 
molecules led us to hypothesize that inhibitor(s) co-targeting all three molecules may 
have the maximum effects on the CSC phenotype. Ponatinib was chosen given its 
inhibition on multiple RTKs, with potency of inhibition on Ephs, Trk and c-kit below 
50 nM level234. The result is astonishing; with nearly complete elimination of HNSCC 
sphere formation, ALDH+ and SP fraction (Figure 4.7.2A-C).  To assess the in vivo 













Table 4.1. Summary of IC 50 for various inhibitors used in the screening and 
their major targets. 
Inhibitor IC50 (µM) Target/s Inhibitor IC50 (µM) Target/s 
Gefitnib 9.56 EGFR Axitinib 1.80 VEGFR 
AZD4547 4.40 FGFR PX866 5.89 pan-PI3 kinase 
OSI906 24.0 IGF-1R, InsR Everolimus 12.92 mTOR 
GNF5837 6.15 TrkA/B/C GSK2334470 6.20 PDK1 
BMS777607 7.12 Axl, RON,Tyro3 LY2157299 50 TGF  receptor 
Imatinib 33.0 c-Kit, PDGFR Paclitaxel 0.08 Microtubule 
















Figure 4.6. Activation of multiple receptor tyrosine kinases (RTK) in 






















Figure 4.6. Activation of multiple receptor tyrosine kinases (RTK) in 
PIK3CA-overexpressing cells. (A.) Chemiluminescent image of RTK protein 
array in the PIK3CA-overexpressing cells (CU110) and control cells (CUCON) 
using the Pathscan RTK Signaling Antibody Array Assay Kit. The quantification is 
shown under the image. (B.) Quantification of RTK protein array in CU110 cells 
stably transfected with either short hairpin sh-PIK3CA or scramble control (SCR).  
(C.) Quantification of RTK protein array in CU110 cells treated with either DMSO 




either DMSO, or ponatinib for 48 hours. Cell were then harvested and viability was 
determined by Vi-cell cell analyzer, 1 x 105 viable CU110 cells after DMSO or 
ponatinib treatment were injected into the syngeneic C57Bl6 mice. 21 days later lung 
tissues were harvested from these two groups of mice. As shown in Figure 4.7.2D, 
CU110 cells generated multiple lung nodules in all four mice injected. In contrast, 
none of the lungs have visible lung modules in the CU110 cell treated with ponatinib.  
To further validate this result in human HNSCC cell lines, we treated 
UMSCC47 and Fadu cells with PX866, LDN211904, GNF5837 and Ponatinib. In 
consistent with the results from CU110 cells, the only effective inhibitors on HNSCC 
sphere formation on either UMSCC47 or FaDu cell lines were LDN211904 (inhibitor 
on Ephrin receptors), GNF5837 (inhibitor on TrKs), and ponatinib (pan-inhibitor on 
Ephrin receptors, TrKs and c-Kit) (Figure 4.7.3). 
 
Discussion 
The major causes of mortality in HNSCC patients are recurrence and 
metastasis, which are highly associated with EMT and CSC traits as shown in our 
study3–5. Studies suggest that HNSCC tumor cells undergo EMT to infiltrate the 
blood supply and  gain CSC properties to survive and generate new tumors either 
locally or distantly123. PIK3CA gene amplification is perhaps the most common 
genetic change in human HNSCC patients38,40,48. To understand the role of PIK3CA 
amplification in HNSCC formation and progression, we overexpressed PIK3CA in 
murine head and neck epithelium, and found that it significantly promoted HNSCC 








Figure 4.7.1. Targeting Ephrin receptors, Trks or c-kit effectively reduce 














Figure 4.7.1. Targeting Ephrin receptors, Trks or c-kit effectively reduce 
CSC population in HNSCC.  (A.) Screening for pharmaceutical inhibitors 
effectively reducing CSC population in CU110 cells using HNSCC sphere forming 
assay. The quantification is shown in right.  (B.) FACS analysis of CD44 (Left) or 
ALDH (Right) in CU110 cells treated with LDN211904. (C.) FACS analysis of 
ALDH in CU110 cells treated with GNF5837. (D.) FACS analysis of CD44 (Left) 
or SP fraction (Right) in CU110 cells treated with imatinib. All experiments were 
done by using CU110 cells treated with specified inhibitor for 48 hours to achieve 








Figure 4.7.2. Ponatinib, a multi-kinase inhibitor targeting Ephs, Trk and c-kit, 
effectively eliminates CSC population in HNSCC.  (A.) HNSCC sphere forming 
assay of CU110 cells treated with ponatinib. The quantification is shown in right. 
Spheres with diameter ≥ γ0 microns were counted. (B.) FACS analysis of ALDH 
in CU110 cells treated with ponatinib. The quantification is shown in right. (C.) 
FACS analysis of SP fraction in CU110 treated with ponatinib (left). The 
quantification is shown in right. (D.) Gross pictures of lung tissues harvested from 
mice received tail vein injection of CU110 cells treated with DMSO or ponatinib. 
All experiments were done by using CU110 cells treated with specified inhibitor 
























Figure 4.7.3. Targeting Ephrin receptors and Trks effectively eliminates CSC 
population in human HNSCC cell lines. Screening for pharmaceutical inhibitors 
reducing CSC population in human HNSCC cell lines: Fadu and UMSCC47, 
using sphere forming assay. The quantification is shown in right. n=3; error bars 
indicate SD. All experiments were done by using either Fadu or UMSCC47 cells 




EMTed, and metastatic HNSCC14. In this chapter,  we focus our studies on 
understanding the role of PI3K pathway in regulating EMT and CSC traits using both 
murine and human HNSCC cell lines.   
Several studies have shown that PI3K pathway promotes EMT and CSC 
properties in human cancers235. For example,  PIK3CA mutation is most frequently 
seen (nearly 50%) in aggressive breast cancers that display EMT and CSC 
properties 215. Breast cancer cell lines engineered with a knocking-in PIK3CA 
mutation display an EMT phenotype216.  PI3K signaling is critical for prostate CSCs 
maintenance and targeting PI3K signaling eliminate these CSCs236. Additionally, 
PI3K signaling cooperates with MEK signaling to maintain self-renewal and 
tumorigenic capacity of glioblastoma CSCs237. PI3K signaling also plays a critical 
role in maintaining colorectal CSCs238. In line with these reports, our study presented 
here shows that overexpression of PIK3CA promotes EMT and CSC phenotype in 
HNSCC.  
However, we surprisingly found that although overexpression of PIK3CA 
promotes EMT and CSC in HNSCC, knocking down PIK3CA failed to reverse either 
EMT or CSC phenotypes. Instead, it appeared to promote the CSC population of 
HNSCC. The PI3K-indepenent mechanism has also been observed in a PIK3AC-
mutatant breast cancer mouse model210. Liu et al observed a subset of recurrent 
breast cancers that no longer responsed to PI3K treatment. These findings together 
with us warrant a precision treatment of using PI3K inhibitors in clinical setting, 
particularly when using PI3K inhibitors for recurrent or metastatic cancer patients.   




through regulating miR-200s in breast cancer208. In addition, we found that the level 
of PIK3R1 is increased in the PIK3CA-overexpressing HNSCCs. However, knocking 
down AKT1, AKTβ or PIKγR1 didn’t reverse EMT and reduce CSC population. 
Instead, it promoted CSC population in the PIK3CA-overexpressing HNSCCs. 
Although genetic suppression of PDK1 reversed EMT14, it failed to affect CSC 
phenotype. Similar to our finding of knocking down PIK3CA, this data raised a 
concern when targeting AKT or other components in PI3K pathway to treat recurrent 
or metastatic HNSCC patients.  
Although it still remains unknown, we suspect that multiple feedbacks and 
pathway crosstalk may be one of the explanations for the PI3K-independent 
mechanism observed in this chapter. One such example is that activation of mTOR 
initiates a feedback loop that attenuates PI3K/AKT activities in breast cancer cells. 
The consequence is enhanced PI3K/AKT activity upon mTOR inhibitor treatment 239. 
Another example is in cancer cells bearing mutant RTKs, blocking PI3K signaling 
resulted in upregulation of  Raf-MAPK pathway to confer tumor growth40,240,241. 
Recently, Pandolfi and colleagues also showed alternative activation of MAPK 
signaling as a compensation mechanism for the mTOR inhibition242. In these cases, 
inhibiting one target/pathway resulted in activating another target/pathway to 
compensate the initial inhibition. In our case, blocking of PI3K signaling may 
potentially activate another molecule/pathway to maintain the CSC population in the 
PIK3CA-overexpressing HNSCCs.  
In light of these results, we speculate that PI3K or AKT inhibitors may not be 




the anti-mitotic agent, docetaxel with or without the pan PI3K inhibitor PX-866 in 
patients with relapsed or metastatic HNSCC showed no difference in response rate 
or overall survival due to the combination treatment with PX-866243. Although PI3K 
or AKT inhibitors are actively undergone clinical trials in human cancers, 
understanding the role of this pathway at different stages of tumor development or 
progression is essential to develop precision treatment on human cancer patients.  
To identify these compensatory mechanisms of PI3K-independency, we 
screened RTKs in this chapter since it is closest signaling potentially interact with 
PI3K pathway. We found that multiple RTKs were activated in the PIK3CA-
overexpressing HNSCCs, with Ephs and Trks signaling the most prominent. Ephs 
are highly expressed in stem cells and in CSC in breast, ovarian, lung, glioma and 
melanoma, and are associated with tumor growth and metastasis244,245. Mutations in 
Trks have also been reported in multiple cancers, including ovarian, colorectal, 
melanoma, and lung246,247. Recent studies have also shown that TrkA and C 
overexpression promotes growth and invasion in a breast cancer model248,249. A 
report also showed that TrkB and C promotes brain tumor-initiating cells250. The role 
of either Ephs or Trks in maintenance of CSC population has been demonstrated in 
this chapter. However, how PIK3CA-overexpression activates these two particular 
pathways in compensating the maintenance of CSC trait in the PIK3CA-
overexpressing HNSCC remains investigation. In addition, the potent elimination of 
CSC population in the PIK3CA-overexpresing HNSCC by ponatinib provide a 
possibility that co-targeting both pathways may achieve the maximum effects of 




Trk may also be affected by ponatinib treatment. Nonetheless,  it seems that 
ponatinib can be one of candidates for clinical trials to  control HNSCC recurrence 
and metastasis, given that this drug has been approved and used in clinic to treat 
leukemia patients with well tolerance251.  
Taken together, our results show that while PIK3CA overexpression promotes 
EMT and enriches CSC population in both murine and human HNSCCs, the 
maintenance of CSC population in HNSCC becomes PI3K pathway-independent.  
Multiple RTK activation, particularly the Ephs and Trk signaling may be alternatives 
to maintain CSC population in the PIK3CA-overexpressing HNSCCs. Thus, targeting 
Ephs and/or Trk pathway may be effective in eliminating the PI3K-independent CSC 
population, and may be developed into novel therapies to treat recurrent and/or 














INHIBITION OF HISTONE DEACETYLASE ELIMINATES CSC POPULATION 
THROUGH REVERSION OF EMT IN HNSCC WITH PIK3CA OVEREXPRESSION 
 
Introduction 
            HNSCCs remain challenging to treat, largely due to cancer recurrence and 
metastasis. These complications significantly contribute to the poor survival rates for 
HNSCC patients3,5. Development of effective therapies that treat HNSCC recurrence 
and metastasis is urgently needed. 
As discussed in the previous chapters, we showed that both EMT and CSC 
traits in the PIK3CA-overexpressing HNSCCs significantly impact cancer 
progression, which can be regulated by both genetic and epigenetic events171. 
Epigenetic alterations  refer to gene expression changes rather than changes of 
nucleotide sequences and  are mainly  regulated through both histone modification 
and DNA methylation169. Histone acetylation and deacetylation are the major 
processes of histone modification to regulate gene expression. Histone deacetylases 
(HDAC) deacetylates lysine residues to condensate  chromatin to suppress 
transcription, while histone acetyltransferase  acetylates and de-condensates 
chromatin to release transcription169,170. DNA methyltransferase transfer a methyl 
group to DNA to repress transcription172. Epigenetic modulation is associated with 
the regulation and maintenance of EMT and CSCs178,252. As tumor cells underwent 
EMT or CSCs frequently possess unique and reversible epigenetic profiles178,252, the 




methyltransferases, present possible targets for new anticancer therapies. 
In previous chapters, we have shown that PIK3CA overexpression promotes 
EMT and enriches CSC population in HNSCCs. However, the maintenance of CSC 
population in these tumors becomes PI3K pathway-independent.  We further 
identified Ephs and/or Trk pathway may be important in maintaining CSC traits in the 
PIK3CA-overexpressing HNSCCs. To further identify other molecules/pathways 
responsible for maintaining CSC traits, in this chapter, we performed an mRNA 
microarray to compare global expression profiles between CSC and non-CSC 
population isolated from PIK3CA-overexpressing HNSCC cells.  Histone 
deacetylation (HDAC) was one of the pathways differentiated regulated in the CSC 
population. Targeting this pathway using HDAC inhibitors effectively eliminated CSC 
population in the PIK3CA-overexpressing HNSCCs, suggesting that HDAC inhibitor 




Transcriptional Profiling Identified Molecular Pathways Related to PIK3CA 
Overexpression-induced CSC Properties 
As discussed in Chapter IV, compare to monolayer culture, sphere forming in 
CU110 cells enriches CSC properties by increased expression of embryonic stem 
cell markers Sox2, Nanog, and Oct4a, and enhanced in-vivo tumorigenicity, and can 
be used as a platform for CSC study.  We thus performed a gene expression array 




cultured cells.   As shown in Figure 5.1A, compared with monolayer-cultured CU110 
cells, there are 1448 genes that are differentially expressed in sphere-cultured cells, 
including 712 upregulated and 736 downregulated genes (genes that have a twofold 
or greater difference in gene expression). Functional cluster analysis using NIH 
DAVID and Affymetrix Transcriptome Analysis Console identified several pathways 
potentially related to CSC phenotype, including cell cycle, DNA replication, ESC 
pluripotency,  epigenetic regulation, focal adhesion-mediated RTK signaling, Adar1 
editing deficiency immune response, and cytokine regulation (Figure 5.1B). The 
slowing cell cycle, DNA replication and enhanced pluripotency reflect general 
characters of quiescent, slow cycling, and pluripotent CSCs. In addition, the changes 
in epigenetic regulation, particularly the upregulation of HDAC9 draw us a great 
attention.  
 
Inhibition of Histone Deacetylase Eliminates CSC Population through 
Reversing EMT 
Aberrant regulation of histone deacetylases (HDACs) have been observed in 
several cancers178, and emerging evidence suggests that histone modification may 
regulate programs related to EMT and CSC phenotype253. The general changes of 
histone modification, particularly the upregulation of HDAC in HNSCC sphere 
promoted us to test whether interfering histone modification affects CSC phenotype. 
We thus applied an HDAC inhibitor apicidin, which targets both class I and class II 
histone deacetylase to the PIK3CA-overexpressing CU110 cells and assessed the 





Figure 5.1. Transcriptional profiles of HNSCC sphere- or monolayer-
cultured CU110 cells. (A.) Hierarchical cluster analysis of Affymetrix Mouse 
Gene 2.0 array showing differentially expressed genes in sphere- or monolayer-
cultured CU110 cells. (B.) Pathways enriched in sphere-cultured CU110 cells 
identified by NIH David and Affymetrix Transcriptome Analysis Console. Genes 
up-regulated (red), or down-regulated (blue) by more than two-fold in each 




5.2A, in contrast with no effect upon PX866 treatment, apicidin treatment completely 
eliminated HNSCC sphere forming ability of CU110 cells.  Apicidin treatment also 
significantly increased CD24+ non-CSC population, with no significant effect on 
CD44+ CSC population in CU110 cells. In contrast, PX866 treatment had no effects 
on CD24 or CD44, populations (Figure 5.2B). To assess whether apicidin treatment 
is able to reverse EMT, we examined E-cadherin expression upon apicidine 
treatment. As shown in Figure 5.2C, apicidin treatment on CU110 cells restored E-
cadherin expression at both mRNA and protein levels. In contrast, apicidn treatment 
had no effect on AKT activation (Figure 5.2D), suggesting the ability of eliminating 
CSC population is likely through reversion of EMT, but not through PI3K/AKT 
pathway.  We further tested several other HDAC inhibitors, i.e Trichostatin A (TSA), 
Valproic acid (VPA), and Vorinostat (also called SAHA) on HNSCC sphere forming 
abilities. Similar to the effect of apicidin treatment, treatment of CU110 cells using 
these HDAC inhibitors also effectively eliminate HNSCC sphere forming abilities 
(Figure 5.2E). In contrast, treatment with a demethylation agent, 5-azacytidine, didn’t 
affect HNSCC sphere formation in CU110 cells (Figure 5.2E). These data suggest 
that instead of DNA methylation, histone modification may play an important role for 
maintaining CSC phenotype.  
To further expand our observation in murine to human HNSCC cells, we 
treated Fadu and UMSCC47 cells with Apicidin and PX866 and assessed the sphere 
forming capacities upon treatment. Similar to the results observed in the murine 
HNSCC cells, apicidin treatment potently eliminated HNSCC spheres while PX866 




Identification of Key Molecular Events Responsible for Anti-CSC Effect upon 
Treatment of HDAC Inhibitors  
The opposite effects on CSC upon treatment by either HDAC inhibitors or 
PI3K inhibitor PX866 provide an opportunity to identify key molecular events 
responsible for the potent anti-CSC effect by HDAC inhibitors. We thus performed 
another microarray analysis on CU110 cells treated by either an HDAC inhibitor, 
apicidin or a PI3K inhibitor, PX866.  We hypothesized that genes exclusively 
affecting by apicidin, but not by PX866 treatment may be responsible for anti-CSC 
effect upon treatment of HDAC inhibitor, and we focused on genes exclusively 
downregulated by apicidin treatment. A total of 1413 and 2857 genes were 
downregulated by PX866 and apicidin treatment, respectively. Among these genes, 
748 were found to be downregulated by either treatment, while 2109 genes were 
downregulated exclusively by apicidin (Figure 5.3A). Gene ontology analysis 
revealed these exclusively downregulated genes to be involved in chromatin 
modification, transcriptional regulation, developmental regulation, regulation of 
kinase activities, cell mobility, regulation of phosphate metabolic processes, 
apoptosis, and regulation of cell junctions and focal adhesions (Figure 5.3A). These 
findings validated effect of apicidin treatment, since the HDAC inhibitor targets 
multiple cellular functions by altering the chromatin status. From these exclusively 
downregulated genes by apicidin, we selected 12 top candidate genes which were 
downregulated the most upon apicidin, but were either upregulated or no significant 
change (<2 folds) upon PX866 treatment. (Figure 5.3B). To assess the role of 






Figure 5.2. HDAC inhibitors reverse EMT and eliminate CSC population in 




















Figure 5.2. HDAC inhibitors reverse EMT and eliminate CSC population in 
the PIK3CA-overexpressing cells.  (A.) HNSCC sphere-forming assay in 
CU110 cells treated with apicidin or PX866 for 48 hours with 40% cell growth 
inhibition. The quantification is shown in right. Spheres with diameter ≥ γ0 
microns were counted. (B.) FACS analysis of CD24 (left), or CD44 (right) in 
CU110 cells treated with apicidin or PX866 with the same method. (C.) qRT-PCR 
(left) or western blotting (right) of E-cadherin in CU110 cells treated with apicidin 
with the same method. (D.) Western blotting of AKT and phosphorylated AKT in 
CU110 cells treated with Apicidin or PX866 with the same method. (E.) HNSCC 
sphere-forming assay in CU110 cells treated HDAC inhibitors Trichostatin A 
(TSA), Valproic acid (VPA), and Vorinostat (SAHA) and demethylation agent 5-
azacytidine with the same method. The quantification is shown in right. Spheres 
with diameter ≥ γ0 microns were counted. (F.) HNSCC sphere-forming assay in 




using lentiviral-based shRNA technique. Among the 12 shRNAs targeting for each 
individual gene, we were able to knock down 9 genes with over 60% efficacy. We 
then cultured these cells in an ultralow, and serum free condition. As shown in 
Figure 5.3C, only cells with VCAM1 knocking down were not able to form HNSCC 
sphere. 
Initial experiment showing the effectiveness of eliminating CSC population by 
knocking down VCAM1 (sh-VCAM1-139) was exciting. However, when we tried to 
validate this result using another shRNA (sh-VACM1-142) targeting VCAM1, we 
didn’t observe similar effect of inhibiting sphere forming as sh-VCAM1-139, although 
the knocking down efficacy in sh-VCAM1-142 was even better than sh-VCAM1-139 
(Figure 5.4B).  Whether the sh-VCAM1-139 has off-target effect on other unknown 
gene(s), or the level of VCAM1 is bi-directional in maintaining CSC phenotype needs 
further investigation.     
 
Discussion 
It has been shown that epigenetic regulation controls EMT and stem cell traits 
in both normal stem cells and CSCs171,178,253. The potent effects of HDAC inhibitors, 
but not the demethylation agent in abrogating CSC population indicated targeting 
HDAC pathway is one of the approaches which can be developed into anti-CSC 
therapy in human cancers. Moreover, the reversion of EMT upon HDAC inhibitor 
treatment highlighted the close link between EMT and CSC phenotypes in this 
scenario. In supporting our notion, several publications have showed the 





Figure 5.3. Screening of key molecular events responsible for anti-CSC 






















Figure 5.3. Screening of key molecular events responsible for anti-CSC 
effect upon treatment of HDAC inhibitors. (A.) Upper: Venn diagram revealing 
changes of global transcriptional profiles upon treatment of a HDAC inhibitor, 
apicidin, or a PI3K inhibitor PX866 by microarray analysis. Lower:  functional 
clustering analysis using NIH David software. (B.) Top 12 candidate genes 
downregulated the most upon apicidine, but upregulated or no significant 
changes (<2 folds) upon PX866 treatment. (C.)  HNSCC sphere forming assay in 
CU110 cells transfected with individual shRNAs as indicated in image. The 
quantification of HNSCC sphere is shown in right. Spheres with diameter ≥ γ0 


















Figure 5.4. Validation of VCAM in maintaining CSC phenotype.  (A.) HNSCC 
sphere forming assay in CU110 cells transfected with either sh-VCAM1-139, or 
sh-VCAM1-142. The quantification of spheres is shown in right bottom. Spheres 
with diameter ≥ γ0 microns were counted. (B.) Western blotting of VCAM1 in 
CU100 cells transfected with either sh-VCAM1-139, or sh-VCAM1-142. SCR: 
scramble control; NSC: non-specific sequence control. GAPDH was used as a 




human cancers254,255. pan-HDAC inhibitors have already been approved by the FDA 
for the treatment of certain cancers, such as cutaneous T-cell lymphoma256,257. 
However, HDAC inhibitors cause global, nonselective gene changes, which brings 
the concerns of its low specificity258. To this point, HDAC9 we have identified from 
microarray analysis becomes an interesting molecule for further investigation. 
HDAC9 is highly expressed in CSC population and that each of the HDAC inhibitors 
we tested is able to target HDAC9. This suggests that it is possible that the anti-CSC 
and EMT-reversing effect of these inhibitors might be at least, partially through 
targeting HDAC9. Interestingly, it has been recently shown that HDAC9 expression 
is associated with poor prognosis in breast cancer and in the response to HDAC 
inhibitors259. In addition to targeting particular HDAC, we also hypothesize that 
certain molecules/pathways downstream of HADC inhibition may be more selective 
and effective to eliminate CSC population of HNSCC. We thus screened genes 
exclusively downregulated upon HDAC inhibitor treatment. However, of the top eight 
candidate genes we screened, genetic knockdown did not reduce CSC population of 
HNSCC. Although there is still possibility that other key molecule(s) we haven’t 
screened might be the essential “linchpin” gene, it is also possible that the anti-CSC 
effect of HDAC inhibitor may be mediated through multiple molecules/pathways. 
Taken together, the data in this chapter demonstrated the connection 
between EMT and CSC traits in HNSCC, and highlighted effectiveness of HDAC 
inhibition in eliminating CSC population. Further investigation on particular isoforms 
of HDAC, such as HDAC9 identified in this chapter, or downstream 




development of more specific and low toxic therapies for treatment of HNSCC 






















IDENTIFICATION AND VALIDATION OF MICRORNAS REGULATING CSC 
PHENOTYPE IN THE PIK3CA-OVEREXPRESSING HNSCC 
 
Introduction 
Previous chapters showed that PIK3CA overexpression promotes EMT and 
enriches CSC population. However, the maintenance of CSC traits is no longer 
dependent on PI3K pathway. By using RTK protein array and mRNA microarray, we 
found that targeting Ephs and/Trk pathway, or histone deacetylation effectively 
eliminated CSC population in the PIK3CA-overexpressing HNSCCs.  In this chapter, 
we hypothesize that certain microRNAs are essential to such maintenance of CSC 
population and modulating these microRNA expression may be effective to eliminate 
CSC population.   
MicroRNAs (miRNAs) are short non-coding RNAs, roughly 20-24 nucleotides 
in length, which regulate mRNA expression. miRNAs participate in multiple signaling 
cascades, such as differentiation, proliferation, apoptosis, and metabolism. 
Dysregulation of miRNA expression has been linked to tumorigenesis and 
dysregulated miRNAs may function as either tumor suppressors or oncogenes. For 
example, miR-17-92 cluster promotes tumorgenesis by promoting proliferation of 
cancer cells and deletion of the complete miR-17-92 cluster slows down Myc-
induced oncogenesis183. miR-21 overexpression is observed in breast cancer and is 
associated with advanced stage, lymph node metastasis and poor prognosis184; 




and in vivo tumor growth185. miR-200 family miRNAs function as tumor suppressors 
and loss of these miRNAs promotes EMT and metastasis186. CSCs, which are linked 
to cancer recurrence and metastasis, are also regulated by miRNAs in oncogenic 
conditions. For example, overexpression of miR-34 reduced CSCs in pancreatic 
cancer260 and miR200 family microRNAs were significantly lost in breast CSCs261. 
To identify microRNAs that are essential for the maintenance of CSC 
population in the PIK3CA-overexpressing HNSCCs, we performed a microRNA 
array to compare the differential expression between CSC population and non-CSC 
population isolated from PIK3CA-overexpressing HNSCCs.  Among the candidates 
we screened, we validated the differential expression of miR18a-5p, miR182-5p, 
miR199a-5p and miR199a-3p in CSC population by qRT-PCR. Our preliminary study 
further found that introducing miR18a-5p mimics or miR199a-5p inhibitor reduced 
CSC population, suggesting these two microRNAs may be important to maintain the 
CSC phenotype in the PIK3CA-overexpressing HNSCCs. Further investigation of 




Identification and Validation of MicroRNAs Differentially Expressed in CSC 
Population Isolated from the PIK3CA-overexpressig HNSCCs 
microRNA (miRNAs) have been reported as important regulators of 
CSCs182,262. In light of this, we postulated that PIK3CA overexpression-induced CSC 




Chapter V, we discussed that enhanced expression of Sox2, Nanog, and Oct4a was 
evident in the spheres formed by CU110 cells. In addition, enriched SOX2+ cells 
were identified in the spheres, strongly suggesting that spheres enrich CSC 
populations. Based on this, we performed Affymetrix miRNA Array analysis to 
compare the differential expression of miRNAs between HNSCC sphere and 
monolayer-growing CU110 cells.  For this analysis, there were 143 miRNAs found to 
be differentially expressed (greater than two folds) in HNSCC sphere compared with 
monolayer-growing cells, including 81 upregulated and 62 downregulated miRNAs 
(Figure 6.1). We selected 18 highly differentially expressed miRNAs as candidates 
for further validation. (Figure 6.2A). qRT-PCR confirmed the differential expression 
results of these candidate miRNAs from miRNA array (Figure 6.2B). We then 
selected 4 microRNAs (miR-18a-5p, miR-182-5p, miR-199a-3p and miR-199a-5p) 
for further functional analysis. 
 
Modulation of miR- 18a-5p and miR-199a-5p Expression Interfered CSC 
Population Isolated from the PIK3CA-overexpressing HNSCCs 
Among the four miRNAs we selected, miR18a-5p and miR182-5p were 
downregulated while miR199a-5p and miR199-3p were upregulated in HNSCC 
sphere. We then transfected miRNA mimics of miR185-5p and miR182-5p, and 
miRNA inhibitors of miR199a-5p and miR199a-3p into CU110 cells and performed 
HNSCC sphere formation assay subsequently.  As shown in Figure 6.3A, while 
introducing miR182-5p or miR199a-3p inhibitor barely affected HNC sphere forming 







Figure 6.1. Identification and validation of microRNAs (miRNAs) 
differentially expressed in HNSCC sphere of CU110 cells. (A.) miRNA profile 
of HNC sphere- or monolayer-growing Cu110 cells using affymetrix microRNA 
microarray 4.0 chips. Left panel: hierarchical clustering of miRNA profile. Right 
panel: list of miRNA candidates for further validation; linear fold change was 
calculated by using bi-weight average signal (Log2) from HNSCC sphere- or 
monolayer-growing Cu110 cells. (B.) Validation of miRNA candidate expression 
in HNSCC sphere- or monolayer-growing Cu110 cells by qRT-PCR. The 










Figure 6.2. Modulation of miR- 18a-5p and miR- 199a-5p expression 
interfered HNSCC sphere formation in Cu110 cells .  (A.) HNSCC sphere 
forming assay in Cu110 cells transfected with miR-18a-5p mimic, miR-182-5p 
mimic, miR-199a-3p inhibitor or miR-199a-5p inhibitor respectively. The 
quantification of sphere is shown in right. Spheres with diameter ≥ γ0 microns 
were counted. (B.) Target genes of miR18a-5p or miR-199a-5p and relevant 




HNSCC sphere forming abilities, suggesting the important role of miR18a-5p and 
miR199a-5p in maintaining the CSC phenotype in the PIK3CA-overexpressing 
HNSCC.  
We are currently utilizing other CSC markers, and performing similar 
experiments in human HNSCC cell lines. In addition, we used TargetScan database 
to predict the potential target genes regulated by these two miRNAs (Figure 6.3B). 
For the miR-18a-5p, there are 248 predicated transcripts with conserved sites. Some 
of the target genes have been implicated in promoting cancer progression263–266. For 
example, NEDD9 promotes lung cancer metastasis through promoting EMT 
phenotypes263. For the miR-199a-5p, there are 516 predicated transcripts with 
conserved sites. In contrast to the miR-18a-5p, miR199a-5p potentially targets 
multiple tumor suppressor such as Sun1267–269. 
 
Discussion 
Emerging evidence suggest miRNAs as key regulators for CSCs which has 
been implicated in cancer recurrence and metastasis. In HNSCC, reduced 
expression of Let-7 miRNA family members contributes to oncogenesis. Let-7a 
inhibits CSC-like properties in developing tumor populations188 and Let-7d 
suppresses EMT in oral squamous cell carcinoma cell lines187. These data support 
our hypothesis that deregulation of miRNA in HNSCC contributes to the acquisition 
of CSC-like properties. Similar to these findings, results from our study suggest that 
miR-18a-5p and miR-199a-5p may be essential for maintaining CSC population in 




cancer are very limited, it has been shown that upregulated miR-199a-5p functions 
as an oncomir in different cancers270,271. TargetScan analysis revealed that miR-18a-
5p targets multiple oncogenes such as CTGF, ORAI3, NEDD9 and IRF2. CTGF has 
been shown to activate pluripotency genes and EMT program in head and neck 
cancer cells264 and ORAI3, NEDD9 and IRF2 have been implicated to promote 
proliferation, migration and invasion in different cancers263,265,266. Thus, miR-18a-5p 
may regulate CSC state through targeting multiple downstream oncogenes and 
could be considered as a tumor suppressor for CSC. In contrast to the miR-18a-5p, 
miR-199a-5p may function as an oncomirs as it targets multiple tumor suppressors 
such as Klotho and SULF1. Klotho has been shown as a tumor suppressor by 
inhibiting insulin/IGF1, p53/p21, and Wnt signaling267 and SULF1 negatively 
modulate many growth factor induced oncogenic signaling272. 
            Our current data on miRNAs is still preliminary, in addition to further validate 
the role of miR18a-5p and miR199-5p in maintenance of CSC population in human 
HNSCCs, we will study the downstream molecules directly regulated by these two 
miRNAs both in murine and human HNSCCs. Besides, we will determine how these 
candidate miRNA expression levels correlate with patient prognosis using a large 
cohort of HNSCC samples or through available bioinformatics databases. These 
experiments may lay the foundation for novel therapies for CSC in HNSCC.  
Directly utilizing miRNAs as therapy has been tested both in academy and 
industry. Currently, modified miRNA inhibitors or mimics such as locked nucleic 
acids (LNAs) -based therapeutic agents273, or packaged with nanoparticles274–276 




assessed for clinical purposes273. For example, miR-34 mimics as a therapeutic 
against primary and metastatic liver cancer has been conducted in phase I clinical 
trial and no harmful events were observed276. In addition, phase II trial of microRNA-
based anti-HCV therapy-miravirsen has been successfully completed and patients 
who received miravirsen showed a dose-dependent reduction in HCV levels without 
major adverse events277. These promising results highlight miRNA therapy as an 
efficient, specific and safe approaches against various pathological conditions. In the 
future, we hope that miRNA-based therapies may also be able to directly eliminate 
CSC population, and to develop as one of the novel treatments for HNSCC 
















The central theme of this thesis is to understand role of PIK3CA amplification, 
the most common genetic changes in human HNSCC patients in progression of this 
devastating disease using in vivo, in vitro and clinical samples approaches.  
In chapter III of this thesis, I presented our study on in vivo role of PIK3CA 
overexpression in HNSCC progression by generating and characterizing a head-
and-neck specific genetically engineered mouse model (GEMM) in which PIK3CA is 
overexpressed. Although overexpression of PIK3CA in murine head and neck 
epithelium didn’t cause tumor formation spontaneously, overexpression of PIK3CA 
significantly promoted tumor progression through increased PDK1 and enhanced 
TGFsignaling. Examination of human HNSCC clinical samples validated the 
finding from the PIK3CA-GEMM. Further characterization of the PIK3CA-
overexpesing mouse tumor tissues revealed that these tumors underwent changes 
of epithelial-to-mesenchymal transition (EMT) and de-differentiation, and gained 
cancer stem cells (CSC) property. In Chapter IV, I further studied the role of PIK3CA 
overexpression in EMT and CSCs phenotypes by using both murine HNSCC cells 
derived from the PIK3CA-GEMM tumor tissues and human HNSCC cell lines. 
Similar to the findings from the PIK3CA-GEMM tumor tissues in vivo, we found that 
overexpression of PIK3CA promoted EMT and CSC phenotypes in vitro.  However, 
knocking down PIK3CA or key components in PI3K pathway failed to reduce, but 
rather enriched the CSC population in the PIK3CA-overexpressing tumors.  We thus 




responsible for maintaining the CSC population in the PIK3CA-overexpressing 
HNSCCs. In chapter IV, we utilized a receptor tyrosine kinase a protein (RTK) array 
to identify and validate that targeting multiple RTK, with Ephrin receptor and Trk the 
most prominent, effectively eliminate CSC population in the PIK3CA-overexpressing 
HNSCCs. In Chapter V, we utilized a mRNA microarray to identify and validate that 
targeting histone deacetylation (HDAC) potently eliminate CSC population in the 
PIK3CA-overexpressing HNSCCs.  In Chapter VI, we utilized a microRNA (miRNAs) 
microarray to identify a few candidate miRNAs, e.g. miR18a-5p or miR199a-5p 
potentially involved in the maintenance of CSC phenotype in the PIK3CA-
overexpressing HNSCCs.  The major discoveries of my thesis are summarized in 
Figure 7.1. 
 
Novel Mechanisms Underlying PIK3CA Overexpression-driven HNSCC 
Progression 
 
Increased PDK1 and Enhanced TGFβ Signaling Drive PIK3CA Overexpression 
– mediated HNSCC Progression 
One of the major findings in chapter III is that instead of AKT, increased 
PDK1 expression level and activation contribute significantly to HNSCC invasion and 
metastasis. Although AKT is taken as the dominant mediator of oncogenic PI3K 
signaling, we didn’t observe differences in AKT activation or expression of AKT 
isoforms between control and PIK3CA-overpressing tumors. This data suggest that 



















been shown that knock-in of hyper active AKT mutant in breast epithelium cells 
could not recapitulate oncogenic PIK3CA mutation44. In addition, AKT activation has 
also been moderately detected in subset of PIK3CA-mutated breast cancer42. 
Interestingly, PDK1, but not AKT is highly active in these breast cancers bearing 
PIK3CA mutations42. Consistent with this finding, in our model system, PDK1, rather 
than AKT, has been identified to facilitate PIK3CA overexpression-driven HNSCC 
progression.  
PDK1 is a serine/threonine protein kinase that phosphorylates members of 
the AGC kinase superfamily, including AKT. Although PDK1 has been implicated in 
cell proliferation, survival and metabolism220, less is known about its role in cancers. 
Recent studies indicate that PDK1 regulates cell migration in lymphocytes92 and 
induces EMT in cardiac development93, suggesting that dysregulation of PDK1 could 
be a potential oncogenic driver for cancers. Indeed, overexpression of PDK1 has 
been observed in human cancers67,94,96; PDK1 expression also correlated with 
pancreatic cancer and melanoma progression67,96. Emerging evidence suggest that 
the role of PDK1 in regulating multiple cancerous phenotypes is not limited to 
activating the AKT.  Novel downstream targets of PDK1 include SGK342, PLC 1223, 
and polo-like kinase 1224. For example, PDK1 directly activates PLC 1 to mediate 
cancer cell invasion and metastasis223.  
In Chapter III, we also found that overexpression of PIKγCA enhanced TGF  
signaling, including elevated production of TGF 1 ligand and increased Smadγ 
expression and activation. In the study, knocking down of PIK3CA attenuated 




suggesting that the PIK3CA-mediated regulation of TGF  signaling is in a cell 
autonomous manner. In addition, pharmacological inhibition of TGF  signaling 
attenuated tumor invasion and metastasis, highlighting the critical role of TGF  
signaling in mediating PIK3CA overexpression-driven HNSCC progression. TGF  
signaling and PI3K/AKT pathway are tightly linked and frequently co-activated during 
tumor progression103,105. Recent studies have revealed multiple insights into cross 
talk between PIγK and TGF  signaling. For instance, PIγK/AKT-regulated signaling 
is able to mediate TGF  receptor-activated signaling at multiple levels225 . Interfering 
with PIγK/AKT pathway attenuated TGF -induced invasive phenotype and reversed 
EMT278. Although crosstalk between PIγK/AKT and TGF /Smadγ signaling is 
evident, less is known for the interplay between PIγK/PDK1 axis and TGF /Smadγ 
signaling. It will be interesting to see whether PI3K/PDK1 signaling interplays with 
TGF /smadγ signaling and how PIγK/PDK1 drives oncogenic TGF /Smadγ 
signaling during the HNSCC progression.  
In our model system, overexpression of PIK3CA activates PDK1 and 
enhances TGF  signaling to confer HNSCC invasion and metastasis, suggesting 
therapeutic targeting of PDK1 and/or TGF  signaling may effectively control HNSCC 
progression. As the downstream molecular mechanisms underlying PI3K/PDK1 
signaling is unknown. It is critical to investigate these mechanisms as outcomes from 
these studies would provide insights into PIK3CA overexpression-driven HNSCC 





PIK3CA Overexpression Promotes EMT and CSC Properties to Drive HNSCC 
Progression 
In Chapter III and IV, we found that overexpression of PIK3CA promoted EMT 
phenotype and enriched CSC population of HNSCC both in vivo and in vitro. EMT is 
an orderly and polygenic process that contributes to tumor invasion and metastasis. 
It has been shown that PI3K signaling interacts with Twist or Snail transcriptional 
factors to regulate EMT in many different cancer types279–281.  PI3K also 
directly/indirectly cooperates with other signaling such as TGF 278, NF-κB282, Ras283 
and Wnt/ -catenin284 to induce and maintain the EMT. These studies disclose the 
complexity of PI3K-mediated EMT mechanisms. CSCs are subsets of cancer cells 
that possess traits of normal stem cells such as self-renewal activity and mediate 
tumor initiation and progression. Several reports recently suggested a link between 
PI3K signaling and CSCs. For example, PI3K signaling is critical for prostate CSCs 
maintenance and targeting PI3K signaling eliminate these CSCs236. PI3K signaling 
cooperates with MEK signaling to maintain self-renewal and tumorigenic capacity of 
glioblastoma CSCs237. PI3K signaling also play critical role in maintaining ALDH+ 
colorectal CSCs238. However, It has also been shown that inhibition of PI3K/mTOR 
pathway induces the generation of gastrointestinal and liver CSCs285,286. These 
studies suggest that PI3K may have a context/tissue-specific role in regulation of 
CSCs. Indeed, we found that overexpression of PIK3CA is necessary to confer EMT 
and CSC characteristics in HNSCC, but is required as a maintainer of these 
phenotypes. In addition, knocking down of PIK3CA or major components of PI3K 




promote the CSC-like phenotypes in our model system. This finding further support 
the notion that PI3K pathway is not required for maintaining CSC phenotype in the 
PIK3CA-overexpressing HNSCCs.  
Failure of affecting EMT and CSC traits by interfering of PI3K signaling could 
be explained by two reasons. One explanation is that inhibition of PI3K signaling 
may activate compensatory pathways that lead to the maintenance of the observed 
EMT and CSC characteristics. Compensatory feedback loops is evident in PI3K 
signaling. One example is that activation of mTOR in some breast cancer cells 
initiates a feedback loop that attenuates PI3K/AKT activities. So by treating these 
tumors with mTOR inhibitors, the cumulative effect is an increase in the activity of 
PI3K/AKT that enhances tumor growth239. Another example is Ras that activates 
both Raf-MAPK and PI3K pathways. In this case, inhibiting the PI3K pathway is 
compensated by an increase in Raf-MAPK signaling that actually drives tumor 
growth240,241. In both these cases, inhibiting the target to stop tumor growth resulted 
in the opposite of desired effects highlighting the complexity and inter-connectively 
of feedback loops and crosstalk between PI3K and other signaling. In our study, 
blocking of PI3K signaling may potentially activate other alternative pathways to 
confer the PIK3CA overexpression-induced EMT and CSC traits. The other 
possibility is that some PI3K-independent mechanisms may solely regulate PIK3CA 
overexpression-induced EMT and CSC properties. In this case, hyperactive PI3K 
signaling may only function as an early trigger for activating other pathways to 





PI3k-independent Mechanisms that Maintain PIK3CA Overexpression – 
induced EMT and CSC Traits 
In Chapter IV, V and VI, we reported identification and validation of alternative 
molecule(s)/pathway(s) responsible for the CSC phenotype which becomes PI3K-
independent. Such examples were recently reported in other human malignancies. 
For example, using a PIK3CA-mutant GEMM for breast cancer, Liu et al found that 
the recurrence of the PIK3CA-driven breast cancer became PIK3CA-independent. In 
this study, subsets of PIK3CA-driven mammary tumors show resistance to PI3K 
inhibition and c-MYC take over the oncogenic role210. In another example of  a BCR-
ABL-driven chronic myeloid leukemia study, CSC subset never acquires addiction to 
the BCR-ABL fusion that drives disease development287. These studies, along with 
our findings strongly suggest that oncogene-driven tumors may not always rely on 
the same oncogene or related pathways for survival advantages.  
In this thesis, three approaches have been used to identify the potential 
target(s)/pathway(s) responsible for the PI3K-independent CSC phenotype. We first 
utilized a RTK protein array to compare PIK3CA-overexpressing HNSCCs and 
control HNSCCs. Our results showed that multiple oncogenic RTKs were activated 
by overexpressing PIK3CA. Since PI3K is an important signaling node that interacts 
with other cellular pathways, it is not surprising to observe that multiple RTKs were 
activated upon overexpression of PIK3CA. In line of this observation, knocking-in of 
PIK3CA mutant in mouse models of human cancers or cancer cell lines also result in 
additional mutations in several other genes and activate alternative pathways along 




Utilization of pharmaceutical inhibitors targeting RTKs identified that ephrin 
receptors (Ephs) and Trk activation are the prominent effectors for maintaining the 
CSC phenotype in the PIK3CA-overexpressing HNSCCs. Indeed, Ephs are highly 
expressed in stem cells and in CSC in breast, ovarian, lung, glioma and melanoma, 
and are associated with tumor growth and metastasis244,245. Not much is known 
about the Trk receptors in stem cell and CSC biology. Although mutations in Trk 
receptors have also been reported in multiple cancers, including ovarian, colorectal, 
melanoma, and lung246,247,292. Recent studies have also shown that TrkA and C 
overexpression promotes growth and invasion in breast cancer model248,249. A report 
also showed that TrkB and C are implicated in regulating brain tumor initiating 
cells250. For HNSCC it was recently shown that over-expression of TrkB resulted in 
altered expression of molecular mediators of EMT, including down regulation of E-
cadherin and up-regulation of Twist293. This report was also confirmed in a murine 
model that reduced expression of TrkB suppressed tumor growth293. It still remains 
unknown how PIK3CA overexpression activates Ephs or Trk pathways. Further 
investigation on the molecular mechanisms underlying PI3K and Ephs or Trk 
activations will provide important insights into PIK3CA-driven HNSCC progression 
and identify novel therapeutic targets to control HNSCC progression. 
The second approach we used to identify potential target(s)/pathway(s) 
responsible for the PI3K-independent CSC phenotype was to compare the global 
expression profiles between CSC population and non-CSC population isolated from 
the PIK3CA-overexpressing HNSCC cells by mRNA microarray analysis.  Several 




ESC pluripotency,  epigenetic regulation, focal adhesion-mediated RTK signaling, 
Adar1 editing deficiency immune response, and cytokine regulation. The slowing cell 
cycle, DNA replication and enhanced pluripotency reflect general characters of 
quiescent, slow cycling, and pluripotent CSCs. Aberrant regulation of histone 
deacetylases (HDACs) have been observed in several cancers, and emerging 
evidence suggests that histone modification may regulate programs related to EMT 
and CSC phenotype169,178,252,253,294. In the study, we found that targeting epigenetic 
regulation by HDAC inhibitors reversed PIK3CA overexpression-induced EMT and 
eliminated CSC population. In contrast, demethylating agent 5-azacytidine didn’t 
affect the EMT and CSC phenotypes in the PIK3CA-overexpressing HNSCCs, 
suggesting that the epigenetic factors involved in maintaining PIK3CA 
overexpression - induced EMT and CSCs are those in histone modification rather 
than DNA methylation. Indeed, it has been recently shown that HDAC inhibition 
impedes EMT, decreases the CSC population and halts clonogenic sphere formation 
in human cancers 254,255. 
While broad-spectrum HDAC inhibitors have already been approved by the 
FDA for the treatment of T-cell lymphoma, the mechanisms of action of these drugs 
are not yet fully understood256,257. HDAC inhibitors cause global, nonselective gene 
changes, which brings the concerns of its low specificity258. Determining which 
specific pathways are involved in the HDAC inhibition’s effect on affecting PIKγCA 
overexpression-induced EMT and CSCs could lead to identify more specific and 
effective therapeutic targets. To this end, we determined genes affected by HDAC 




were exclusively downregulated by Apicidin treatment and that can be grouped into 
multiple functional clusters such as chromatin modification, transcriptional regulation, 
developmental regulation, regulation of kinase activities, cell mobility, regulation of 
phosphate metabolic processes, apoptosis, and regulation of cell junctions and focal 
adhesions. This finding, once again highlighted the multiple effects of the HDAC 
inhibitor. Unfortunately, targeting each candidate genes by a shRNA approach failed 
to abrogate CSC population in the PIK3CA-overexpressing HNSCCs, although initial 
experiment showed some promising result of targeting VCAM molecule. These data 
suggest that there is a possibility that a combinatorial effect targeting multiple 
molecules might be effective although we cannot rule out the possibility of the 
mechanism involving a single essential “linchpin” gene. Future studies into the roles 
of these identified genes and their relevant pathways may yield novel specific 
therapies for targeting CSC population in the PIK3CA overexpressing HNSCCs. 
Emerging evidence suggest certain microRNAs may regulate CSCs in human 
cancers. For example, overexpression of miR-34 reduced CSCs in pancreatic 
cancer260 and miR200 family microRNAs were significantly lost in breast CSCs186,295. 
Thus, the third approach we used to identify potential target(s)/pathway(s) 
responsible for the PI3K-independent CSC phenotype was to compare the global 
expression profiles between CSC population and non-CSC population isolated from 
the PIK3CA-overexpressing HNSCC cells.  Using microRNA microarray analysis, we 
identified over 100miRNAs were differentially expressed in CSC-enriched spheral 
cells compared with monolayer-growing non-CSC cells. Of these differentially 




CU110 cells significantly reduced sphere-forming capacity. These data suggest a 
suppressive role for miR-18a-5p and a promoting role for miR-199a-5p in 
maintaining PIK3CA overexpression-induced CSC state. Although there are few 
studies involving miR-18a-5p in cancer, it has been shown that upregulated miR-
199a-5p functions as an oncomir in gastric cancer270. In addition, miR-18a-5p targets 
multiple oncogenes such as CTGF, ORAI3, NEDD9 and IRF2263–266 while miR-199a-
5p targets multiple tumor suppressors such as Klotho and SULF1267,272. Further 
investigation of the potential target genes regulated by these miRNAs is ongoing. 
These experiments may lay the foundation for identifying miRNAs and targets to 
improve current therapy for HNSCCs. 
Interestingly, relevant works present in Chapter V revealed that reversing 
EMT program by HDAC inhibitor reduces CSC properties, which indicates that EMT 
and CSC properties are tightly linked process. However, relevant data from Chapter 
IV also indicate that attenuation of CSC properties is not necessarily associated with 
reversing of EMT program, which suggest that EMT and acquisition of CSC 
properties can be also uncoupled processes. Although different groups have 
recently revealed that acquisition of CSC properties by activating stemness-related 
signaling pathways such Wnt, has also been involved in some aspects of the EMT 
program296–298. Other groups also have indicated that EMT can suppress major 
attributes of stem cell properties299. Indeed, overexpression of EMT-related 
transcription factors in CSC-enriched populations induced EMT phenotypes, but 
suppresses their CSC properties such as self-renewal and metastatic phenotypes300. 




cancer cell population induces epithelial phenotype and properties of CSC300. These 
data suggest the sophistication and complexity of the cross-talk between EMT/MET 
and stemness and its relevance in cancer progression and metastasis. PIK3CA 
overexpression-induced EMT process clearly contributes to the acquisition of CSC 
properties. However, whether the acquired CSC properties still depends on the EMT 
left a question that necessitates further studies.  
 
Novel Therapeutic Strategies for Treating HNSCC with PIK3CA Alteration 
Currently, the only Food and Drug Administration-approved targeted therapy 
for HNSCC is EGFR inhibitors33. However, resistance, recurrence and metastasis 
still remain the major factors for treatment failure of HNSCC patients 196,197. For 
example, RTK inhibitors such as gefitnib and erlotinib are extensively studied for 
treating recurrent and/or metastatic HNSCC. Unfortunately, both drugs were barely 
effective for controlling HNSCC progression and gefitinib doesn’t improve survival 
rates over those of methotrexate201. As PIK3CA appears to be the most frequently 
altered oncogene in HNSSC, PI3K-targeted therapy are currently evaluated in 
clinical trials as either monotherapy or in combination with radiation and/or 
chemotherapy regimens in patients with HNSCC301. Although there is a biologic 
basis for the use of PIγK inhibitors to treat HNSCC, the effıcacy of these agents is 
less satisfactory. For example, in a randomized phase II trial in recurrent and/or 
metastatic HNSCC patients, the pan -PI3K inhibitor PX866 was administered with 
cetuximab, but it did not show any clinically benefıt302. In addition, a phase II trial of 




metastatic HNSCC showed no difference in response rate or overall survival upon 
the combination treatment243. Given the lack of effective treatments for HNSCC and 
the rising incidence of disease, there is an urgent need for novel therapies 
particularly effective in controlling HNSCC recurrence and metastasis. 
In our study, one of the promising targets to control HNSCC progression is 
PDK1. In supporting this, genetic or pharmacological suppression of PDK1 showed 
to reduce CSCs and metastasis in several human cancers96,224,226. In addition, 
targeting PDK1 by pharmaceutical inhibitors has been shown to be effective to 
reduce tumor size of HNSCC222. The other potential target is TGF  signaling. 
Although TGF -targeted therapy has been evaluated for a decade in multiple 
cancers, it remains unclear how it may be efficiently used227. TGF -targeted 
therapies are highly stage- and patient-specific. Thus, identifying appropriate 
patients by using stage-wise biomarkers are critical for the success of such 
therapies. As both activated PDK1 and enhanced TGF  signaling are concurrent in 
our model system, combinatorial targeting of PDK1 and TGF  may effectively 
control PIK3CA-driven HNSCC progression. 
In our study, we found that inhibition of PI3K pathway either genetically or 
pharmaceutically failed to reduce but rather promote the CSC population in the 
PIK3CA-overexpressing HNSCC. This finding raised a question about how to utilize 
PI3K inhibitors for clinical management of HNSCC patients. Although PI3K inhibitors 
are still remain a promising targeted therapy, our findings questioned the 
effectiveness of this treatment for controlling recurrence and metastatic HNSCC 




identified suggest that targeting Ephsand/or TrK may be effective to control 
recurrence and metastasis of HNSCC patients. Although using pharmaceutical 
inhibitors targeting either Ephs or Trk were effective in reducing CSC population, this 
is further exemplified by the potent abrogation of CSC population using ponatinib. 
Ponatinib has been approved by FDA for the treatment of adults with chronic 
myeloid leukemia and acute lymphoid leukemia with well tolerance251. Another 
potential therapeutic drug is HDAC inhibitors, which are currently actively developed 
for multiple clinical trials with vorinostat and romidepsin are approved by FDA for 
treating refractory cutaneous T-cell lymphoma258. Thus, our data provide 
experimental evidence of applying ponatinib or HDAC inhibitors for clinical trials to 
treat HNSCC progression, particularly to treat recurrent or metastatic HNSCC 
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